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Fmoc  9H-fluoren-9-ylmethoxycarbonyl 
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HATU  1-[bis-(dimethylamino)methyliumyl]-1H-1,2,3-triazolo[4,5-b]pyridine-3-oxide 
HPLC  high-performance liquid chromatography 
ihDA/rDA inverse-electron-demand hetero-/retro-Diels–Alder reaction 
Leu  leucine 
MACOS  microwave-assisted continuous-flow organic synthesis  
MS  mass spectrometry 
NCE new chemical entities 
NMM   N-methylmorpholine 
PFP   pentafluorphenyl 
pTSA  para-toluenesulfonic acid 
rDA   retro-Diels-Alder 
RP   reversed-phase 
SPPS   solid-phase peptide synthesis 
TentaGel  polyethylene glycol–polystyrene copolymer resin without any linker 
TMS  trimethylsilyl
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1. INTRODUCTION AND AIMS  
The pharmaceutical industry is still under tremendous pressure to deliver new and 
successful drugs to the market. To meet this demand requires continuous change by 
providing new strategies and innovative solutions to improve and speed the journey 
from early discovery to production. Synthetic chemistry plays a key part in the drug 
discovery process. New reactivity patterns are discovered every day, along with new 
reactions and applications of established reactions. In terms of laboratory-based 
techniques to support these efforts, continuous-flow (CF) processing is emerging as one 
of the techniques that can significantly impact the synthetic process.1,2 
This interest can be explained, at least in part, by the number of potential advantages 
that CF processes have over traditional batch chemistry.3-5 Namely, the well-regulated 
flow reactor concept provides an increased parameter space for chemical synthesis and 
enables reactions to be performed with an unprecedented level of control. It is due to the 
greatly enhanced heat and mass transfer and improved mixing properties,6,7 which can 
translate into higher product quality. A further advantage is that reactions can be carried 
out at high temperature and pressure accredited to superheating of organic solvents in an 
inherently greater safety resulting from the small reactor volumes. The accurate tuning 
of flow reactor parameters, e.g. residence time, can further govern the outcome of 
chemical reactions by determining the reaction rate and the conversion as well as 
influencing product selectivities.8-10 Thus, flow chemistry has long been selected to 
provide a simple means to use more rigorous reaction conditions and revisit difficult 
reactions that have been neglected in the past.  
Focusing on the latter understanding, our major aim was to probe the versatility of 
the CF technology by developing novel sustainable synthetic methodologies with 
possible usefulness for the pharmaceutical industry. For this purpose, a study was 
conducted where the following areas were reinvestigated comparing classical batch 
methods to CF-based techniques: i) retro-Diels–Alder (rDA) reaction [II], ii) cyclisation 
reactions, i.e. a three-step domino ring-closure reaction and spirocyclisation 
(cyclocondensation) [III], iii) synthesis of β-peptide foldamers via CF solid-phase 
peptide synthesis (SPPS) followed by rDA reaction [I, IV]. 
Cyclic β-amino acids have embraced significant interest in organic and medicinal 
chemistry since they can be widely applied as key moieties in peptide chemistry, in drug 
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design, and in heterocyclic and combinatorial chemistry. Moreover, enantiomerically 
pure β-amino acids and their derivatives are used as chiral auxiliaries or chiral building 
blocks in asymmetric synthesis.11-17 Herein, the CF benefits have been harnessed to 
improve our synthetic pathway by searching a time-efficient access to pharmaceutically 
relevant intermediates and potentially bioactive compounds in a safe, simple and 
efficient manner, starting from β-aminonorbornene carboxylic acid derivatives [I-IV]. 
The rDA reaction is an important tool for synthetic chemists in their search towards 
the synthesis and design of novel heterocyclic scaffolds. However, it has been less 
explored compared to its parent reaction (Diels–Alder) due to the harsh reaction 
conditions involved. The endothermic requirements of rDA have led to the use of high 
temperature conditions, which make it an ideal reaction to be performed under CF 
processes, where high heat and mass transfer are operative. rDA reaction represents a 
straightforward and an efficient approach to various racemic and enantiomeric fused 
pyrimidinones [II,III] as valuable new chemical entities (NCE), with diverse 
pharmacological potentials.18,19 
In pharmaceutical applications, foldamers play the role as a novel class of drug 
scaffolds with tailored molecular shape and surface. These unnatural oligomers have 
strong tendency to adopt specific and predictable conformations in solution.20,21 Some of 
the most thoroughly investigated foldamers are the β-peptides, which possess additional 
biomimetic properties akin to natural -peptides including hierarchical self-
organisation,22 conformational polymorphism and real folding reactions.23-25 By 
application of the CF rDA reaction on homooligomer peptides containing [1R,2R]-2-
aminocyclohexanecarboxylic acid ([1R,2R]-ACHC) units possessing an enantiomeric 
bicyclic residue in the middle of the chain, the effect of new structural elements on 
conformation was studied too [IV]. It is known that in the case of -peptides the 
formation of the homochiral peptide from a racemic starting mixture is still ambiguous 
compared to natural α-peptides. Through the investigation of the stereochemical 
discrimination in the synthesis of -peptides towards the homochiral oligomers, we 
wanted to gain an insight into the origin of biological homochirality [I]. 
Publications on which the thesis is based are referred to in square brackets, while 
other references are given as superscripts. 
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2. THEORETICAL BACKGROUND  
2.1. Principles behind the use of flow reactors 
CF reactors have been increasingly used in synthetic organic chemistry to facilitate 
chemistries, which are otherwise difficult to carry out. It has affected many fields over 
the last 20 years. A broad range of research in which CF reactors have been propagated 
includes catalysis,26-28 nanoparticle synthesis,29 sensors,30 electrochemistry31 and 
polymerisation.32 On the basis on channel diameter, CF reactors can be broadly divided 
into microscale, mesoscale, and large scale.33 Compared with the conventional batch 
method, reactors whose flow channels have hydraulic diameters of below 1 mm offer 
several advantages, such as improved heat and mass transfer as a consequence of the 
increased surface area to volume ratio.34-37 Precise temperature control enables 
suppression of by-product formation.38,39 Other benefits include efficient mixing,40 
higher conversion and selectivity,41,42 reduction of the environmental burden and 
increased process safety through the minimisation of reagent and solvent quantities.43 
Various basic variances between classical batch experiments and the CF methods can 
be deduced (Figure 1).44,45 For instance, in standard reaction vessels the conversion 
depends on the reaction time, whereas in a CF apparatus a continuous stream of reactant 
flows through the reactor channels where the transformations take place, and the 
conversion becomes a function of the distance covered in the reactor.46 As a 
consequence, the chemical process becomes space-resolved. 
 
     Traditional chemical reactor      Continuous-flow reactor     
Key factors: 
  Concentration 
  Mixing 
 
 Temperature 
 Reaction time 
 Key factors: 
 Residence Time 
 Mixing 
 
 Heat and mass transfer  
 Pressure 
Figure 1. Principle of traditional batch reactor vs. CF microreactor. 
While the flow rate is controlled by means of conventional HPLC pumps 
(hydrodynamic flow), other means, such as electroosmotic or centrifugal flow are also 
possible.47 In a continuous process, the reaction time is assigned as the interval spent by 
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a given molecule in the active reactor zone and is referred to as the residence time.6 The 
conversion correlates with the residence time and can easily be fine-tuned through 
adjustment of the flow rate or varying the channel length. By screening different types 
of reactions allows the selection of those, which may be suitable for turning from batch 
to continuous processes. A few classes of reactions that may take advantage of 
microreactors and flow conditions are as follows: i) extremely fast reactions may be 
exploited by improving mixing and general transport phenomena; in addition, improved 
heat transfer should effectively prevent hot spot formation (e.g. organometallic 
reactions), ii) kinetically controlled rapid reactions, where a strict control over 
temperature and residence time may improve selectivity (e.g. coupling reactions), iii) 
hazardous reactions that may be carried under more controlled conditions by using flow 
systems, which also limit hazards due to decreased volumes.48-51 
Mixing efficiency. Mixing is highly influential in the conversion and selectivity of 
reactions. In batch reaction vessels, the mixing is mainly achieved by classical 
mechanical stirring through turbulence at high Reynolds numbers (Re) that is the fluid 
elements exhibit a random motion, which facilitates convective mass transport 
(Figure 2a).7 In contrast, the laminar flow of the fluids distinguishes microreactors from 
classical CF reactors.7,47 Hereby, the fluid elements flow in parallel lamellae and mixing 
is governed by molecular diffusion only (Figure 2b).52 Laminar flow has the advantages 
of restraining gradient formation in concentration, temperature, pressure, volume and 
time. Furthermore, the complex channel structure in microreactors generates secondary 
flow structures at high flow velocities, which lead to very efficient and fast mixing. 
Transport limitations are therefore reduced with respect to conventional reactor 
configurations. This leads to important applications in process intensification.53 
According to Fick’s law, the velocity of diffusion depends on the channel diameter, 
which clearly suggests that miniaturisation of the axial dimensions can dramatically 
enhance the mass transfer in flow reactors.54 Moreover, the mixing properties in 
capillary channels can be further improved by using concentric or parallel streams 
rather than straight lines, and many flow setups include an initial mixing zone prior to 
the inlet of the actual reactor.5 
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Figure 2. Concentration profiles for mixing (a) in batch, (b) in the CF reactor simulated 
for a neutralisation reaction between HCl (A) and NaOH (B).55 
Mass transfer/Heat exchange. One of the most claimed advantages of the modern 
compact-scale CF reactors is the enhanced heat and mass transfer, compared with 
conventional batch processes.5 Mass transfer is a key element of many chemical 
transformations; the increased surface area-to-volume ratio of microreactors effectively 
increases mass transfer.4,55 Efficient and rapid mass transfer can dramatically reduce the 
reaction time and improve the reaction rate relative to conventional batch experiments. 
The temperature in flow reactors depends on the kinetics of a chemical reaction.56 In a 
complex reaction network with several parallel and sequential reactions, the product 
distribution is strongly influenced by the temperature of the system. In the course of a 
chemical reaction, heat is exchanged via the reactor surface and, therefore, the surface 
area-to-volume ratio is a critical factor in efficient reactor design. Heat exchange in 
microreactors is sufficiently efficient that even highly exothermic reactions can be 
conducted under nearly isothermal conditions47 with improved production safety.5,57 
Even explosive reactants58 or highly unstable intermediates can be handled easily.59 On 
the other hand, the superior heat absorption abilities in flow channels can greatly reduce 
the reaction times of endothermic transformations. This is in contrast to large-scale 
reactors where significant axial and radial temperature gradients exist. By quickly 
responding to temperature changes, the formation of undesired by-products can be 
successfully suppressed.55,60 As a result of the effective heat and mass transfer, an 
additional advantage is the much better reproducibility of CF reactions as compared 
with those in a conventional apparatus.46 High temperatures in the CF technology are 
most commonly attained through the use of external ovens, and built-in Peltier elements 
can be used to achieve better control over temperature. Microwave dielectric heating 
6 
 
has also been integrated into flow devices, and indirect inductive heating techniques 
have recently been introduced. 
Pressure control. When the dimensions are small, even very high pressures result in 
only modest forces on the reactor walls. Moreover, high pressures can be attained easily 
in capillary microreactors, and reactions have been carried out safely at pressures above 
400 bar.56 Consequently, microreactors are ideal for studying reactions at high 
temperature and pressure.61 Examples of chemical reactions under high pressure 
conditions of CF processes are cycloadditions, Diels–Alder (DA) reaction, condensation 
reactions, etc. Pressure increases the miscibility of liquids and the solubility of solids or 
gases enhances synthetic efficiency. High-pressure conditions are widely employed in 
CF reaction technology, as modular backpressure valves ensure simpler access to harsh 
conditions than conventional high-pressure autoclaves.62 The contained environment 
and the ease of pressurizing in modern CF reactors remove the boiling point barrier and 
allow the superheating of solvents in a safe and simple manner, thereby providing novel 
process windows in an increased parameter space for chemical synthesis.63,64 Under 
very high temperature/pressure (T/P) conditions, an unprecedented amount of energy 
can be supplied to chemical reactions, which leads to improved kinetics and, 
consequently, the dramatic shortening of reaction times, even in transformations with 
very high activation barriers.64,66 With suitable apparatus, even supercritical conditions 
can be achieved for many organic solvents. 
2.2. Application of CF in the synthesis and transformation of heterocycles 
2.2.1. Cycloaddiditon and cyclcondensation reactions 
Cycloaddition and cyclocondensation reactions are important in the synthesis of 
heterocycles. They have been prepared in flow to afford a range of valuable 
N‐heterocycles with high biological activities and offer synthetic diversity when 
generating compound libraries.67-75 In traditional batch-based methodologies such 
reactions present a challenge (particularly on a relatively large scale), because reaction 
conditions can be harsh in order to attain acceptable yields. Accordingly, in order to 
deliver these entities in a flexible, high-yielding fashion, avoiding time-consuming 
purification procedures as well as hazardous or obnoxious chemical inputs wherever 
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possible, the flow chemistry methodology has been adopted, at least in part, by the 
number of potential advantages that CF processes have over traditional batch chemistry. 
There are several key demonstrations of these reactions under flow conditions. One 
of the first examples was introduced by Ley et al. using eight parallel microcapillary 
flow discs (MFDs).76 The MFD reactor was constructed from a flexible, plastic 
microcapillary film (MCF) comprising parallel capillary channels with diameters in the 
range of 80–250 µm. MCFs were wound into spirals and heat treated to form solid 
discs, which were then used to carry out CF reactions at elevated temperatures and 
pressures with a controlled residence time. Employing this reactor, the authors 
demonstrated the scalable synthesis of tetrahydroisobenzofuran derivative 1 via DA 
reaction as illustrated in Scheme 1a. To perform the reaction, reactant solutions were 
brought together under a pressure-driven flow, where they were mixed prior to heating 
in a microcapillary flow reactor, using a flow rate of 6 mL min-1 within a residence time 
of 28 min. The authors obtained the target product 1 with almost full conversion and in 
an isolated yield of 98%, which equates to an impressive throughput of 3.9 kg day-1 of 
the final crystalline product. 
More recently, Organ et al. reported a series of DA reactions conducted in Pd-coated 
capillaries through microwave-assisted continuous-flow organic synthesis (MACOS) 
processed in a single reactor (Scheme 1b).77 The combination of microwave heating and 
CF reactor design has long been realised as an ideal marriage of technologies. The 
feasibility of this system was first demonstrated by Strauss78 and since then a number of 
groups have offered their own solutions. They addressed scale-up issues of microwave-
assisted reactions, with the limited penetration depth of microwave irradiation into 
absorbing media and the physical limitations on the dimensions of a standing wave 
cavity, by combining CF processing with microwave heating.79-83 When Organ et al. 
performed the reaction in the absence of a Pd coating in an oil bath at 205 °C, only a 
moderate conversion to (1R,4S)-dimethyl-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-
dicarboxylate (2) was obtained. This was subsequently increased upon employing a Pd-
coated capillary. Utilizing microwave irradiation as a means of heating the flow reactor, 
the authors found the best conversion to the DA product when the Pd coating was in 
contact with the reactant (catalytic effect). Much lower activities were obtained with the 
reactor coated outside (due to a thermal effect) or completely in the absence of Pd. 
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Based on these findings, a series of DA cycloadditions were performed, whereby 
conversions were consistently higher than those obtained in an oil bath.  
 
Scheme 1. Examples of DA cycloadditions conducted in flow.  
Moreover, macroporous monolith reactors are also applied in a variety of organic 
transformations investigating several strategies to prepare monolithic microreactors in 
flow reactions.84-86 For example, Galarneau et al. developed alumina-grafted macro- and 
meso-porous silica monoliths (Al-MonoSil, 6 mm diameter, 1–4 cm length) as CF 
reactors for the DA reaction between cyclopentadiene and crotonaldehyde.87 Given the 
moderate Lewis acidity and the interconnected system of 5-μm macropores within the 
monolith, the Al-MonoSil behaved as a suitable heterogeneous catalyst for efficient 
CF DA reaction with only a low pressure drop (0.5 atm). This system delivered high 
conversion and productivity of 13 kg adduct per week and per liter of the monolith 
catalyst. Both Al-MonoSil and zeolites have Brønsted and Lewis acid sites with suitable 
porosity for organic reactions. Recently, Stevens et al. achieved the DA reactions of 
cyclopentadiene (3) and methyl acrylate (4) under CF conditions catalyzed by 
heterogeneous H-Beta type zeolite (Scheme 2a).88 The use of H-Beta type zeolite with 
the largest pore diameter and surface area gave a high conversion (>95%) and end-
selectivity (89:11) using a 1:1 stoichiometry of diene and dienophile. The catalytic 
activity and the productivity of the adduct under the flow process were 3.5 and 14 times 
higher, respectively, compared with the lab-scale batch process. Moreover, the zeolite 
catalyst could be used multiple times by including a 5-h calcination step to regenerate 
the used zeolite. 
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Asymmetric DA reactions using chiral heterogeneous catalysts under CF conditions 
have also been achieved. As an illustrative example, the Luis group developed chiral Ti-
TADDOLate immobilised on cross-linked polystyrene monolith and carried out the 
flow reaction of cyclopentadiene with 3-crotonoyl-1,3-oxazolidin-2-one.89 In this study, 
however, the flow process using the obtained chiral heterogeneous catalyst afforded low 
yield and enantioselectivity that is it had no significant advantage compared with the 
batch process. On the other hand, the heterogeneous organocatalyst worked efficiently 
in the addition of Et2Zn to benzaldehyde under CF conditions. Benaglia et al. developed 
an immobilised MacMillan-type imidazolidinone catalyst on silica and a cross-linked 
polystyrene monolith and examined their catalytic activity. The CF reaction between 
cyclopentadiene and cinnamylaldehyde (5) with the packed-bed reactor of the 
heterogeneous MacMillan-type catalyst maintained stable conversion with good 
enantioselectivity over several days (Scheme 2b).90 The polystyrene monolith was then 
studied in the 1,3-dipole addition of N-benzyl-C-phenyl nitrone with 
cinnamylaldehyde (5).91 However, because of the extremely low turnover frequency of 
this catalyst, this process required long contact times of 12.4 h for full conversion of 
substrates, and achieved low productivity. 
 
Scheme 2. Examples of catalyzed DA reactions performed in CF mode: (a) H-Beta type 
zeolite catalyst, (b) monolithic reactor for CF stereoselective cycloaddition. 
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Another example of the DA cyclisation was reported by Djuric et al. for the synthesis 
of benzoisoindolines and benzoisoquinolines through inter- and intra-molecular DA 
cycloaddition of ortho-quinodimethanes (o-QDMs) as shown in Scheme 3a.92 These 
highly reactive dienes are accessed through the thermal electrocyclic ring-opening of 
benzocyclobutenes. Due to the aromaticity of these systems, this reaction occurs 
typically with flash vacuum pyrolysis (FVP) or with prolonged heating in high-boiling 
solvents, thus greatly limiting its application in drug discovery programs. Djuric et al. 
adapted a new methodology by applying a modified and automated high T/P Phoenix™ 
flow reactor. The instrument is capable of achieving up to 450 °C and 200 bar of 
pressure and allows the use of superheated conventional solvents and, therefore, 
reaction times can be dramatically shortened.92 By employing the same reactor, the 
research group also synthesized several libraries of fused pyrimidinone and quinolone 
derivatives via the Gould–Jacobs reaction (Scheme 3b).93 The condensation of an aryl 
amine with an alkoxymethylene compound followed by thermal ring-closure reaction 
under high T/P flow conditions allowed the synthesis of fused pyrimidinone and 
quinolone derivatives in good to high yields within 0.5–8 min. 
 
Scheme 3. (a) Inter- and intra-molecular DA cycloadditions of o-QDMs. (b) Reaction 
sequence leading to Gould–Jacobs-type products. 
Ley et al. reported the cyclisation via 1,3-dipolar cycloaddition of non-stabilised N-
(methoxymethyl)-N-(trimethylsilyl)benzylamine (6) with nitroalkenes 7 using flow 
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reactors.94 A solution of the alkene and trifluoroacetic acid (TFA) required to generate 
the dipole was flowed through a T-piece, where it was combined with a stream of the 
azomethine ylide precursor (Scheme 4a).94 The combined stream was then passed 
through a heated reactor coil and subsequent scavenger columns in order to remove any 
unreacted alkene. By using this method, 10 different examples of 3-nitropyrrolidine 
scaffolds were synthesized in good yields (74–93%). A similar cycloaddition reaction 
has also been reported in flow by the Fray group.95 The same azomethine ylide 
precursor (6) was used to synthesize the pyrrolidine ring. Using different alkene 
substrates, they were able to perform the reaction at 70 °C in 10 min (Scheme 4b). 
 
Scheme 4. Examples of 1,3-dipolar cycloaddition for the synthesis of pyrrolidine.  
In their work synthesizing pyrazoles under high T/P flow conditions, Kappe et al. 
prepared varied inhibitors of canonical transient receptor potential channels (TRPC).96 
The use of high temperatures allowed the condensation of hydrazines with enones 
enabling the fast synthesis of several pyrazoles. Subsequent palladium-catalyzed 
Buchwald–Hartwig amidation under microwave conditions afforded a range of 
bioactive TRPC inhibitors in good yields. Another application of high temperature flow 
conditions for heterocycle formation was reported by Herath and Cosford.97 
Microreactors were used to perform a Hantzsch pyrrole synthesis using HBr generated 
during the reaction to directly hydrolyze tert-butyl acetoacetate ester 8 to afford pyrrole-
3-carboxylic acids 9a-h (Scheme 5a). 97 Product acids could also be further reacted with 
amines to the corresponding amides. A further report by Cosford et al. demonstrates the 
synthesis of thiazoles making use of high temperature microreactors in a two-step 
12 
 
synthesis (Scheme 5b).98 Initially, the condensation of -bromoketones with thioamide 
gives β-ketothiazoles by the Hantzsch thiazole synthesis. A stream of aldehyde with 
urea was then combined with the main stream and heated for 10 min yielding 
dihydropyrimidinones 10 via the Biginelli reaction. The same research group reported 
the two-step synthesis of imidazo[1,2-a] heterocycles using microreactors.99 
 
Scheme 5. Examples of cyclocondensation reactions in flow.  
Furthermore, Mason et al.100 presented a series of cyclodehydrations of a number of 
Bohlmann–Rahtz aminodienones illustrating the use of CF processing to transfer 
operations from commercial microreactors and microwave batch reactors to mesoscale 
production using different technology platforms, including a microwave flow reactor. It 
is noteworthy that CF processing offers ready automation, improved reproducibility, 
enhanced safety and considerable process reliability, whereas microwave heating 
promises improved kinetics and even selective coupling, thus providing opportunities 
for the rapid processing of materials. As a last example, the end-to-end multistep CF 
setup reported by Ley et al. is briefly discussed here.101 It is a four-step conversion of 
anilines into N-arylated pyrazoles via amine-redox cycle followed by hydrolysis of the 
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hydrazine surrogate ensuing cyclocondensation. The telescoped flow process offers a 
distinct advantage over the corresponding batch procedures due to the in situ formation 
and use of several reactive intermediates. Critically, this end-to-end style of synthesis 
avoids the stock-piling and storage of hazardous drug intermediates (diazonium salts 
and hydrazines) by directly advancing them to the next step as they are produced. 
2.2.2. Retro-Diels–Alder reaction 
Heterocyclic skeletal transformations are among the most powerful synthetic 
strategies for the construction of complex molecular frameworks from simple 
feedstocks.102-104 In this context, the DA and rDA reactions are the prevailing 
approaches, since they lead to valuable N-heterocycles of high biological activity, such 
as isoindolo-, pyrrolo- and 2-spiro-quinazolinones. The DA reaction comprises a 
reversible [4+2] cycloaddition between a conjugated diene and a substituted alkene 
(dienophile). The reverse process of the DA reaction is the rDA reaction as illustrated in 
Scheme 6.105 
 
Scheme 6. DA/rDA reaction of cyclohexene 
The thermal [π4+π2s] cycloreversion of an organic compound containing a double 
bond in a six-membered ring leads to the formation of a diene and a dienophile (DA 
adducts). This pyrolytic dissociation arises when one or both fragments are notably 
stable.106 The unsaturation present in the original starting material is protected in the 
DA adduct, and the same atoms are involved both in the bond formation and bond 
cleavage steps.107-109 The rDA process is an efficient technique for the introduction of a 
double bond into a heterocyclic skeleton110 as well as for the enantiodivergent111 and the 
enantiocontrolled112 syntheses of heterocyclic compounds. A particular characteristic of 
the DA/rDA approach makes use of the rigidity and chirality of the DA adducts, which 
are attainable in reactions between cyclic dienes and cyclic dienophiles. Because of the 
endothermic nature of rDA fragmentation, high temperatures are usually needed in 
order to overcome the high activation barrier of the cycloreversion. In some cases, 
extreme conditions such as FVP (at 600–900 °C), shock tube, photochemical (laser) 
activation or the use of gamma-radiation are required. Although these methods have 
14 
 
several advantages, the end products often undergo rearrangements or decomposition. 
Application of the rDA under traditional batch conditions for the laboratory-scale 
preparation of heteromonocycles or condensed-ring heterocycles has been widely 
examined and discussed.113-117 rDA products can be gained by distillation under reduced 
pressure,118 boiling in a solvent,119,120 and applying microwave irradiation121-124 or 
FVP.124,125  
The harsh reaction conditions required for rDA coupled with the problems associated 
with instability of the products under these conditions have prompted chemists to look 
for alternate mild conditions for effecting rDA reactions. Various efforts were 
undertaken in this direction; for instance, the inclusion of trimethylsilyl (TMS) group or 
by creating a strain in the molecule.126,127 The trimethoxysilyl group imparts a positive 
effect on rDA reactions by lowering the activation energy.128 It is possible to perform an 
rDA reaction under mild conditions by judiciously incorporating a heteroatom in the 
DA adduct. The Kotha group reported a novel observation performing the rDA reaction 
by introducing a cyclopropane ring at C-7 of the norbornene system.129 This result 
clearly indicated that an increased delocalisation in the transition state involving the 
cyclopropane orbitals is responsible for the bond-breaking process and thus increasing 
the rate of the rDA reaction. Noteworthy, the thermal rDA reaction of anthracene 
cycloadducts can speed up by electron-donating groups. In a similar manner, the 
incorporation of an oxide anion substituent strongly accelerates the rDA process 
too.130,131 
Flow chemical approaches have been found to ensure better control of chemical 
processes due to improved heat and mass transfer. Unconventional and harsh reaction 
conditions such as greatly elevated temperatures and pressures can be generated easily 
allowing the superheating of organic solvents far beyond their boiling point in a 
controlled and safe manner. The rDA reaction, for its characteristics such as being a 
thermally-driven process, is an ideal reaction to be performed in CF. In spite of this, 
precedents are scarce. In fact, the CF rDA method was utilised only once by the Myers 
group performing the preparation of a precursor intermediate for the construction of 
diverse tetracycline antibiotics.132 As an illustration, a solution of reactants (0.02 M) 
were dissolved in diphenyl ether and pumped continuously using a peristaltic pump 
through a stainless-steel tube submerged in an oil bath heated to 250 °C at a flow rate of 
12 mL min-1 (Scheme 7). 
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Scheme 7. rDA reaction for the preparation of an intermediate of tetracycline 
antibiotics. 
By applying these conditions, the authors obtained rDA product 11 in a moderate 
yield (55%). Due to the difficulties of handling the CF reactor and the use of a large 
volume of high-boiling solvent, the authors headed towards the development of an 
alternative protocol to perform the rDA reaction. The use of 
dimethylsilylcyclopentadiene was particularly appealing because of its simplicity and 
the possibility that 5-silylcyclopentadiene might be recycled. Thus, by using this 
method, the authors could get retrodiene product 11 in an improved yield (87%) 
compared to those achieved by the CF method. 
Moreover, there are a few other examples, which might be related to the application 
of rDA reaction under CF conditions. For example, Martin et al. introduced the 
synthesis of annulated pyridines from 2-substituted acetylene pyrimidines under 
superheated CF conditions by an intramolecular inverse-electron-demand hetero-/retro-
Diels–Alder reaction (ihDA/rDA).133 The flow system was equipped with a high-
temperature 316 stainless steel tube flow reactor placed into a GC oven and a 250 psi 
back-pressure regulator (BPR). Using this stable and scalable flow process, a series of 
annulated pyridines were produced in good to excellent yields and in significantly 
reduced reaction times when compared to the corresponding batch process. In the same 
context, Blanchard and coworkers reported the synthesis of various polycyclic fused- 
and spiro-4-aminopyridines from pyrimidines through a [4+2]/retro-[4+2] cycloaddition 
between a pyrimidine and an ynamide, which constitutes the first examples of ynamides 
behaving as electron-rich dienophiles in [4+2] cycloaddition reactions.134 In addition, 
running the ihDA/rDA reaction in the continuous mode in superheated toluene to 
overcome the limited scalability of MW reactions, results in a notable production 
increase compared to batch mode. 
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2.3. Application of CF in the synthesis of β-peptide foldamers 
Foldamers are artificial self-organizing biomimetic polymers,135-142 similar to natural 
peptides, proteins, RNA and DNA. These systems have a strong tendency to form 
highly stable and versatile secondary structures, such as helices, strands and turns 
(Figure 3).142-145 Foldamers have numerous biomedical activities.146,147 There are 
antibacterial amphiphills,148 cell and membrane penetrating peptides,149 anti-Alzheimer 
compounds,150 and compounds effectively modulating protein–protein interactions.151 
Based on this fact, they are nowadays considered as proteomimetics.146 Some of the 
most thoroughly investigated foldamers are the β-peptides,152 which possess additional 
biomimetic properties akin to natural β-peptides including hierarchical self-
organisation, conformational polymorphism, and real folding reactions.23 
 
Figure 3. β-Peptide foldamers: (a) general substitution pattern of β-peptides and (b) 
examples of β-peptide secondary structures. 
Foldamer synthesis is generally achieved by two methods: i) solution-phase synthesis 
and ii) solid-phase peptide synthesis (SPPS) either with a tert-butoxycarbonyl/benzyl 
(Boc/Bzl)153 or with a 9-fluorenylmethoxycarbonyl/tert-butyl (Fmoc/tBu)154 technique. 
2.3.1. Continuous-flow solution-phase peptide synthesis 
In solution-phase peptide synthesis, two protected amino acids are mixed in the 
presence of a suitable activator/base in the liquid phase. This method was used for the 
first synthesis of [1R,2R]-ACHC homooligomers by applying Boc for amino protection 
and the benzyl ester for carboxyl protection with the activation performed with 1-ethyl-
3-(3-dimethylaminopropyl)carbodiimide (EDCI) and 4-(N,N-dimethylamino)pyridine 
(DMAP).135 However, this method suffers from various drawbacks: the reaction time is 
very long and carbodiimide activation can lead to racemisation. Furthermore, decreased 
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solubility caused by the protected oligomer can give truncated sequences resulting in 
difficulties in product purification. To avoid the mentioned difficulties and the need for 
more complex peptides, SPPS has been applied. In addition, significant effort has been 
devoted to developing CF solution-phase peptide assembly protocols. For instance, 
Haswell et al. demonstrated the synthesis of di- and tri-β-alanine (Ala) peptides using a 
borosilicate glass microreactor in which reagents were mobilised by electroosmotic 
flow (EOF).155-158 The method involves the use of a photolithographic technique and 
wet etching for fabricating microchannel in the reactor with materials comprised of 
negatively charged functional groups (Scheme 8). The bulk solvent flow was induced 
by EOF and the direction and magnitude of the flow may be readily altered by varying 
the applied voltage. Within this miniaturised systems, a solution of reagents (0.1 M), 
Fmoc-β-alanine, EDCI and dimethylamine borane (Dmab) ester of β-alanine, used in 
the reaction were placed, respectively, in the reservoirs A, B and C, whereas reservoir D 
was used to collect the products (Scheme 8). Platinum electrodes were placed in each of 
the reservoirs and an external voltage was applied to the channels inducing EOF of the 
reagents. For 20 min, at room temperature, only a moderate conversion to the final di-β-
Ala peptide 12 was observed. By using dicyclohexylcarbodiimide (DCC, 0.5 M) as an 
alternative carbodiimide coupling reagent, the dipeptide was afforded in a good yield of 
93% (Scheme 8a). Furthermore, this protocol was successfully employed in the 
synthesis of tripeptide 13 involving a preactivated pentafluorphenyl (PFP) ester, albeit 
with a low yield of 30% (Scheme 8b). 
 Scheme 8. Schematic representation of flow-based microreactor used for the 
preparation of (a) β-alanine di-peptide and (b) β-alanine tri-peptide.157 
When utilizing mechanical pumping, Flogel et al. introduced the synthesis of a series 
of tetra-β-peptides using a silicon-based CF microreactor.159 They have also claimed 
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that this synthesis was the first (i) to achieve Boc and Fmoc amino acid coupling in only 
1–5 min at high temperature (120 °C); (ii) to use β2- and β3-homoamino acids 
containing a fluorous benzyl group, with the aim to facilitate the purification via 
fluorous solid-phase extraction (FSPE) for β-peptide synthesis; and (iii) to show the 
relevance of a C10H4F17-substituted benzylic ester protecting group in solution-phase 
coupling. The flow reactor was designed to be compatible with a wide range of organic 
solvents and can be operated over a broad temperature range (–80 °C to +150 °C) with a 
total prequench volume of 78.3 mL. The system was utilised to furnish tetrapeptide 14 
(Scheme 9). Assembly of tetrapeptide 14 was first conducted by forming the β3–β3 
peptidic bond, which was synthesised at 90 °C in 3 min with 2 equiv. of the acid 
fluoride [Boc-β3h(R)Ala-F] and 4 equiv. of N-methylmorpholine (NMM). The 
formation of the sterically more demanding β3–β2 peptide bond required higher 
temperatures and extended residence time with a maximum conversion obtained at 120 
°C in 5 min [2 equiv. of acid fluoride Boc-β3h(R)Val-F, 4 equiv. of NMM]. The final 
β2–β3 coupling was also established at 120 °C in 1.5 min and the tetramer was obtained 
in an overall yield of 81%. 
 Scheme 9. (a) Schematic representation of the microreactor showing the three inlets: 
A = acid fluoride; B = amino acid benzyl ester; C = NMM, D = the outlet and quench 
port (TFA and the internal standard); (b) β-peptide synthesis via CF in the solution 
phase.159 
  
19 
 
2.3.2. Continuous flow solid-phase peptide synthesis (CF-SPPS) 
This technique is based on the reaction of an N-protected amino acid immobilised on 
an insoluble support usually a polymer, in most cases, through the carboxylic function. 
The reaction is extended by the removal of N-protection and the addition of the second 
protected amino acid. The excess reagents used are removed by simple washing and 
filtration. Although SPPS has advantages features, it has several drawbacks, including 
the requirement of an expensive resin, and additional steps like attachment of the first 
amino acid to the resin and its final removal. In this regard, microreactors could 
overcome some of these shortcomings. Moreover, the long coupling times may be 
reduced by the application of microwave-assisted SPPS.160 Thus, a CF-SPPS mesoscale 
reactor consisting of HPLC-based modules, which allowed the construction of peptides 
and foldamers with only 1.5 equiv. amino acids, has been developed by our research 
group.161 The reactor consists of an HPLC pump for liquid delivery, an autosampler 
injecting the reagents necessary for peptide synthesis, mainly the deprotection solution 
and the coupling mixture. The coupling mixture can be prepared directly by the 
autosampler or can be premixed manually before the synthesis. The resin is filled into 
the HPLC column and heated by a column thermostat. Finally, a pressure regulator is an 
important part of the system. Through a complete reaction parameter optimisation, all 
20 proteinogenic amino acids can be coupled with only a 1.5-fold excess of amino 
acids. The technology was tested by the synthesis of two difficult sequences. In both 
cases, the CF-SPPS technology showed superior performance compared to microwave-
assisted SPPS technology when only a 1.5-fold excess was utilised. Such a low excess 
is tremendously important in the coupling of artificial, exotic and expensive amino 
acids, which are used for the construction of foldameric systems. By the utilisation of 
the CF-SPPS technology, various foldameric systems were assembled (The schematic 
representation of the reactor is shown in the Materials and Methods section; page 21, 
Figure 5). 
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3. MATERIALS AND METHODS 
3.1. Continuous-flow protocols 
Continuous-flow retro-Diels–Alder (CF rDA) reactor: CF rDA reactions were 
performed on a modular flow system equipped with heated 304 stainless steel tubing 
coil with 14 mL internal volume [Supelco premium grade 304 empty stainless steel 
tubing; dimensions: length (L) × outer diameter (OD) × inner diameter (ID) = 100 
ft×1/16 in×0.03 in; product number 20553] and an adjustable back-pressure regulator 
(ThalesNano, BPR, 0–300 bar). The tube reactor was heated in a Heraeus oven to the 
desired temperatures (Figure 4). Solutions of the starting materials were loaded into the 
reactor via an HPLC pump. The most important reaction parameters such as 
temperature, pressure, flow rate and substrate concentration were systematically fine-
tuned to determine optimal conditions. The residence time was set by the use of coils 
with different lengths. The crude products were analysed by thin-layer chromatography 
and, if necessary, column chromatographic purification was carried out. The products of 
the CF reactions were characterised by means of NMR (1H, 13C), HPLC–MS and FT-IR 
spectroscopy. In the cases of chiral compounds, ee was assigned with a Phenomenex IA 
column. 
 
Figure 4. Setup of the continuous-flow retro-Diels–Alder reactor. 
Continuous-flow solid-phase peptide synthesizer (CF-SPPS): Peptides were synthesized 
by using a standard solid-phase technique utilizing the CF-SPPS reactor constructed 
previously.161 The CF reactor consists of an HPLC pump, an HPLC injector or 
autosampler, a cylindrical fillable HPLC PEEK column, and an HPLC BPR as shown in 
Figure 5. 
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Figure 5. Schematic representation of the CF-SPPS reactor.162 
CF hydrogenation reactor: Reactions were performed in an H-Cube® flow reactor 
apparatus equipped with a gas-generation unit consisting of a reservoir for deionised 
water and a built-in electrolysis cell for the generation of H2. The gas generated in situ 
is combined via a gas–liquid mixer with the solution of the substrate, and then the 
mixture is transported to the catalyst (10% Pd/C) bed, where the triphasic reaction takes 
place.  
3.2. Synthesis  
Pyrimidinone-fused moieties prepared by flow synthesis:   
Domino ring-closure and spirocyclisation reactions: Racemic or enantiomeric β-
aminonorbornene carboxamide (1 mmol) and γ-keto acids or cycloalkanones 
(1.2 mmol) were dissolved in toluene or ethanol (EtOH) (50 mL). The system 
temperature in the flow rector illustrated in Figure 4 was set to 100 °C, the pressure to 
10 bars and the flow rate to 0.2 mL min-1. When the pressure and the temperature of the 
flow system were stable, the solutions were loaded into the reactor passing through the 
heated reactor coil. Within a reaction time of 6 h, the flow output was collected. The 
solvent was removed by evaporation and the solid residue was, if necessary, dissolved 
in a mixture of ethyl acetate and methanol (EtOAc/MeOH) (9:1 v/v) and transferred to a 
neutral SiO2 column, or simply crystallised in Et2O and the crystals were filtered and 
washed with Et2O. The analytical and spectroscopic data of the intermediate 
pyrimidinone derivatives were identical to those found in the previous batch methods. 
Retro-Diels–Alder reaction. The racemic or enantiomeric intermediate pyrimidinone 
derivatives (100 mg) were introduced into the flow reactor (Figure 4) in a solution of 
acetonitrile (MeCN) or toluene or toluene/MeOH (4:1, 25 mL). The pressure was kept 
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at a constant value of 10 bars and the flow rate was varied in the range 0.5–0.2 mL min-
1. The solutions were pumped into the reactor and passed through the heated reactor coil 
at 150–250 °C, within a residence time of 10–60 min and collecting the flow output. 
The solvent was removed by evaporation, the residues were either crystallised in Et2O 
(5 mL) or transferred to a SiO2 column, dissolved and eluted in EtOAc/MeOH (9:1). 
The analytical and spectroscopic data of the retrodiene products were identical to those 
found in the previous batch and in microwave processes. Details of syntheses, physical 
and analytical data on new compounds described in the thesis and descriptions of NMR 
spectroscopic analyses can be found in the experimental parts of the enclosed 
publications.[II, III] 
Peptide synthesis: Peptides were synthesized on a solid support by means of CF-SPPS 
(Figure 5) involving Fmoc chemistry with chain lengths of the oligomers varying 
between 3–6 units. The peptide chains were elongated on TentaGel R RAM resin 
(0.19 mmol g-1) carried out manually on a 0.1-mmol scale. Couplings were performed 
with HATU/DIPEA {HATU = [2-(7-aza-1H-benzotriazol-1-yl]-1,1,3,3-
tetramethyluronium hexafluorophosphate, DIPEA = N,Ndiisopropylethylamine} 
without difficulties. The formed peptide sequences were cleaved from the resin with 
TFA/H2O (95:5) at room temperature in 3 h. TFA was then removed and the resulting 
free peptides were solubilised in aqueous AcOH (10%), filtered and lyophilised. The 
crude peptides were purified by using reversed-phase HPLC (RP-HPLC). 
CF hydrogenation: Reactions were performed in an H-Cube® flow reactor apparatus. 
The unsaturated precursor purified previously was dissolved in MeOH and 
hydrogenation was carried out on 10% Pd/charcoal catalyst (50 atm, 1 mL min-1 flow 
rate). Characterisations were performed by using HPLC–MS. 
Diastereodiscriminative peptide coupling: Peptide solutions (0.01 mmol) were prepared 
separately with HOBt (0.12 mmol) and DIC {HOBt = hydroxybenzotriazole; DIC = 
N,N′-diisopropylcarbodiimide} (0.12 mmol) in CH2Cl2/DMF (2:1) in the absence or in 
the presence of water (2:1:1) followed by adding Boc-protected racemic amino acids 
(0.1 mmol). The mixtures were stirred for 48 h, CH2Cl2 was removed by evaporation, 
and water was added to the residue followed by lyophilisation. The products were 
treated with TFA/H2O (95:5) to remove the Boc protecting group. The solutions were 
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then stirred for 30 min, TFA was removed in vacuo, the residue was diluted with water 
and then lyophilised. Samples were analysed by HPLC–MS. 
3.3. Analytical investigations 
HPLC measurements: Crude peptides were purified by using RP-HPLC over a 
Nucleosil C18 (7 μm) 100 Å column (16 mm×250 mm). All structures were analysed by 
HPLC–MS with a Phenomenex 5 μm C18(2) 100 Å column (250×4.60 mm). Solvent 
systems consisted of AcOH (0.1%) in water (A) and AcOH (0.1%) in MeCN (B); 
gradient: 5%–100% B over 35 min, at a flow rate of 1 mL min-1. Chromatograms and 
spectra were recorded in positive ionisation mode with electrospray ionisation (ESI) on 
a Thermo LCQ Fleet mass spectrometer. 
Nuclear magnetic resonance (NMR): Fused pyrimidinone moieties were measured at 
ambient temperature, with a Bruker AM 400 or Bruker AscendTM 500 spectrometer 
using tetramethylsilane as internal standard. 1H-NMR spectra were recorded at 400.13 
MHz or 500.20 MHz and 13C-NMR spectra were recorded at 100.62 MHz or 125.77 
MHz in CHCl3 or d6-DMSO. 
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4. RESULTS AND DISCUSSION 
4.1. Continuous-flow retro-Diels-Alder decomposition of pyrimidinone-fused 
moieties 
Fused pyrimidinone derivatives are well known for their pharmacological properties. 
These compounds have several therapeutic applications as anticancer,163 interferon 
inducer,164 antiviral,165 anti-hypertensive,166 hypoglycaemic,167 anticonvulsive,168 anti-
histaminic169 and anti-inflammatory drugs.170 The pyrrolo- and pyrido[2,1-
b]quinazolinones include well-known alkaloids isolated from a number of plant 
families. Because of these therapeutic interests, their syntheses have been studied very 
thoroughly.171 Herein, we have designed a novel synthetic process for the preparation 
and transformation of distinct pyrimidinone-fused moieties, such as 
pyrrolopyrimidinones, pyrimidoisoindoles, and spiropyrimidinones, by means of the 
highly-controlled CF rDA reaction.[II, III] 
4.1.1. Preparation of the intermediate functionalised pyrimidinone derivatives 
To test the viability of our CF rDA protocol, the intermediate quinazolinone 
derivatives (starting materials) were selected to comprise; i) molecules where good, 
medium and no conversion was observed under batch rDA conditions, ii) more complex 
racemic or enantiomeric fused pyrimidinone moieties, iii) molecules which have never 
been subjected to rDA reactions under batch conditions. The intermediate 
pyrimidinones 16–38 have been previously prepared by literature methods. Cyclisation 
of the corresponding amino acids or esters 15a–c with ethyl p-chlorobenzimidate 
resulted in tricyclic diexo or diendo pyrimidinones 16, 17b and 17c (Scheme 
10).110,116,172-175 
 
Scheme 10. Synthesis of the tricyclic pyrimidinone derivatives 16, 17 b,c. 
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Furthermore, the preparation of methanopyrrolo-, methanopyrido- and 
methanoazepino[2,1-b]quinazolinones 18–21 was processed by ring enlargement of 
diexo-norbornene-fused azetidinone 5d with lactim ethers (Scheme 11).176 
  
Scheme 11. Synthesis of quinazolinone derivatives 18–21. 
For the preparation of methylene- and ethylene-bridged 2-thioxopyrimidinones 22, 
23b and 23c, the most common method is the reaction of the appropriate amino esters 
15a–c with phenyl isothiocyanate, followed by cyclisation of the resulting thiourea with 
hydrogen chloride under reflux (Scheme 12).172,175 
 
Scheme 12. Synthesis of thioxopyrimidinone derivatives 22, 23 b,c. 
Moreover, the cyclisation of racemic diexo-3-aminobicyclo[2.2.1]hept-5-ene-2-
carboxamide 15e or diexo-3-N-methylbicyclo[2.2.1]hept-5-ene-2-carboxamide 15f with 
γ-oxocarboxylic acids in toluene under reflux in the presence of para-toluenesulfonic 
acid (pTsA), through three-step domino reactions, resulted in single diasteroisomers of 
pyrrolo[1,2-a]quinazolines 24–26 or isoindolo[2,1-a]quinazolines 27–29 (Scheme 
13).177,178 
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Scheme 13. Synthesis of pyrrolo- and isoindolo[2,1-a]quinazoline derivatives 24–29. 
Upon heating with cyclohexanone under reflux in EtOH, β-aminonorbornene 
carboxamides 15e, 15g and 15h were cyclised to give methylene- and epoxy-bridged 2-
spiroquinazolinones 30–32.179 These compounds could alternatively be prepared under 
dry (solvent-free) conditions by stirring for 2 days.180 Spiropiperidine derivatives 33–35 
were formed by the condensation of carboxamides 15e, 15g and 15h with 1-
benzylpiperidin-4-one in water at room temperature,180 or under reflux in EtOH 
(Scheme 14). For the preparation of spiro[quinazoline-2,2′-adamantane] derivatives 36–
38, we developed an alternative synthetic pathway involving the use of microwave 
irradiation on 15e, 15g, 15h with adamantanone in EtOH (Scheme 14). This reaction 
has previously also been carried out in a vibrational ball mill with iodine (I2) as a 
catalyst.181 
 
Scheme 14. Synthesis of spiroquinazolinone derivatives 30–38. 
In addition, we wanted to develop further this cyclisation reaction by searching for a 
time-efficient method for the synthesis of functionalised intermediates 24–38. To this 
end, a CF-based strategy seemed highly appropriate, since this approach has emerged as 
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an intensely studied area of current research, being used for the synthesis of many 
different heterocyclic scaffolds.93 β-Amino amides 15e–15h were mixed with γ-keto 
acids or cyclic ketones and loaded into the CF reactor constructed previously (Figure 4), 
using the same operating conditions and solvents used before in batch syntheses. 
Mixtures of 15e or 15f and γ-keto acids were dissolved in toluene and introduced into 
the flow reactor at 110 °C, with 6 h as the reaction time. Tetra- and pentacyclic 
derivatives 24–29 were obtained in slightly higher yields (79–93%) than found 
previously in batch method. Heating the solutions of 15e, 15g, or 15h with 
cycloalkanones in EtOH at 100 °C gave spiroquinazolinones 30–38 with reaction times 
of 6 h in similar yields (79–95%). Note, however, that shorter reactions were needed for 
cyclisation in CF reactor. 
4.1.2. CF rDA method development and validation 
Our next step was to investigate the transformation of quinazolinone derivatives 16–
38 into the retrodiene products 39–53 through thermal [4+2] cycloreversion involving 
the elimination of cyclopentadiene, cyclohexadiene or furan from DA adducts. To this 
end, a modular flow system was designed as illustrated in Figure 4. The reactor coil was 
heated in an oven to the desired temperature and solutions of starting materials 16–38 
were loaded into the reactor via an HPLC pump. Solvents were selected on the basis of 
the solubility of the starting materials. The rDA reaction is basically a thermally-driven 
process. Consequently, by careful reaction parameter optimisation, a balance should be 
found between the desired rDA cycloreversion reaction and the unwanted thermal 
degradation of the rDA product. The conversion and yield of a reaction under CF 
conditions are influenced directly by the residence time and reaction temperature, which 
are crucial determining factors in flow chemistry.8-10 Thus, these two parameters were 
fine-tuned and the full reaction parameter optimisation is shown only for compound 16 
in Table 1. 
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Table 1. Reaction parameter optimisation by increasing the conversion and minimising 
the degradation of the product by the example of compound 16. 
 
Entry 
Temperature 
[°C] 
Residence time 
[min] 
Conversion 
[%] 
Degradation product 
[%] 
1 200 10 64 - 
2 210 10 82 - 
3 220 10 83 - 
4 230 10 86 0 
5 240 10 100 7 
6 250 10 100 18 
7 230 15 100 0 
8 230 30 100 13 
In order to validate our protocol, we initiated the CF rDA investigation of tri- and 
tetracyclic derivatives 16–23, since these molecules gave good (>80%), medium (70–
80%) and no conversion under batch rDA conditions. The tricyclic diexo-2-(4-
chlorophenyl)tetrahydro-5,8-methano-4(3H)-quinazoline (16) was dissolved in MeCN 
and first the effect of the temperature was studied. The results showed that with 10 min 
residence time the best conversion value (86%) was obtained at 230 °C (Table 1, entry 
4). It should be noted that at higher temperature, a significant amount of degradation 
product was observed and brown oil was isolated (Table 1, entries 5 and 6). To further 
improve the conversion, the residence time was increased by utilizing longer coils 
(Table 1, entries 7 and 8). Complete conversion could be obtained at 15 min residence 
time and the desired rDA product 39 was isolated with 92% yield (Table 1, entry 7, 
Table 2, entry 1). With longer residence times, again, degradation of the product was 
observed (Table 1, entry 8). Importantly, the complete reaction parameter optimisation 
was carried out only in 105 min. The parameters of the optimised reaction conditions 
for all starting materials and related results are summarised in Table 2. 
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Table 2. Results with the use of the CF rDA process for the synthesis of pyrimidinone 
39–44 under the optimised reaction conditions. 
 
In the case of diendo-isomer 17b, higher temperature (250 °C) but a shorter 
residence time was satisfactory to isolate 39 in a yield of 95% (Table 2, entry 2). 
Furthermore, we proceeded to investigate the elimination of cyclohexadiene from 
compound 17c. Because of solubility reasons, the solvent was changed to toluene, 
which is known to be compatible with high-temperature conditions.133 Retrodiene 
product 39 was afforded with full conversion and in a good yield of 93% (Table 2, entry 
3), which is higher than the maximum yield (85%) reached in our previous batch 
work.115 Importantly, this result was achieved with a residence time of 30 min. 
 
Entry 
Starting 
material 
CF rDA 
 Product 
CF optimised reaction conditions 
Solvent 
Temp 
[°C] 
Residence     
time [min] 
Yielda  
[%] 
1 16 
 
MeCN 
 
230 15 92 
2 17b 250 10 95 
3 17c Toluene 230 30 93 
4 18 
 
MeOH 
130 10 95 
5 19 
 
150 10 97 
6 20 
 
120 10 95 
7 21 
 
130 10 94 
8 22 
 
MeCN 
 
210 15 96 
9 23b 220 10 96 
10 23c 250 30 30 
a Isolated yield. 
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Subsequently, tetracyclic methanopyrrolo-, methanopyrido- and methanoazepino[2,1-
b]quinazolinones 18–21 were examined. Because of their excellent solubility, reactions 
were carried out in MeOH (Table 2, entries 4–7). Importantly, much milder reaction 
conditions gave satisfactory results. With the utilisation of 120–150 °C and only 10 min 
residence time, full conversions to the retrodiene products 40–43 were obtained in high 
yields (94–97%). Lower yields were previously found (70–80%) using a batch process, 
even upon melting compounds 18–21 for 20 min.176 
The effect of the thioxo group on the rDA reaction was investigated too with 
compounds 22, 23b and 23c. In the case of 22, a yield of 96% was reached at full 
conversion at 210 °C in 15 min residence time (Table 2, entry 8). In the reaction of 23b 
(the diendo isomer of 22), a slightly higher temperature with an appropriate residence 
time of only 10 min was satisfactory to have 44 with an isolated yield of 96% (Table 2, 
entry 9). 
On the basis of these encouraging results, we decided to further examine the scope 
and limitation of the CF rDA reaction. For this purpose, diendo-3-phenyl-2-
thioxohexahydro-5,8-ethanoquinazolin-4(1H)-one (23c) was selected, since this 
compound did not lose cyclohexadiene to form monocyclic 44 under batch and 
microwave conditions.175 A solution of 23c in MeCN was treated in the heated coil 
reactor at 250 °C, with a residence time of 30 min. Importantly, according to HPLC–MS 
analysis, compound 23c underwent thermal decomposition but only a moderate 
conversion (36%) was detected and 44 was isolated by means of column 
chromatography with a yield of 30% (Table 2, entry 10). This result is due to the lack of 
the quasi-aromatic character of the leaving cyclohexadiene, and possibly also due to the 
temperature limitation of our system. Surprisingly, however, we could detect traces of 
diendo-3-phenyl-4a,5,8,8a-tetrahydro-5,8-ethanoquinazolin-4(3H)-one (45), resulting 
from desulfurisation of 23c (Scheme 15). This observation prompted us to investigate 
whether desulfurisation can occur under flow conditions. In the literature, a similar 
desulfurisation batch reaction was performed with nickel catalysis, in EtOH/water (2:1) 
solution.182 Thus, thioxo derivative 23c was dissolved in this mixture, and the CF 
method was repeated. Desulfurisation of 23c, at 250 °C without adding any catalytic 
metal, provided tricyclic 45 in good yield (90%). Most probably, the reaction was 
catalyzed by nickel, a component of the 304 stainless steel reactor coil.183 These results 
also underline the importance to select appropriate solvents and tubing184 for thermally-
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driven reactions. In support of our results, tricyclic 45 was also prepared in another 
way: the mixture of 3-aminobicyclo[2.2.2]oct-5-ene-carboxylic acid, triethyl 
orthoformate, aniline and acetic acid was subjected to microwave irradiation at 120 W 
at 80 °C for 20 min. After completion of the reaction, as monitored by TLC, 20% 
methanolic solution in water was added to get precipitation. The solid was filtered off 
and washed with water to get diendo-3-phenyl-4a,5,8,8a-tetrahydro-5,8-
ethanoquinazolin-4(3H)-one 45 (65% yield). 
 
Scheme 15. Synthesis of tricyclic ethanoquinazolin-4(3H)-one 45. 
A further attempt was made to perform the rDA reaction with 45 at 250 °C with a 
residence time of 15 min in MeCN. However, the formation of 46 was not observed, 
that is the starting tetrahydroquinazolinone derivative 45 did not undergo a thermally-
driven rDA reaction (Scheme 15). Furthermore, by applying the same conditions on 44, 
no desulfurisation occurred and the formation of 46 was not detected either. 
There are previous literature results with respect to the preparation of pyrimidinones 
39–44 under batch conditions.115,172-176 These were performed by: i) heating under neat 
conditions or ii) heating under reflux in solvents having a high boiling point 
[chlorobenzene (CB) or 1,2-dichlorobenzene (DCB)], and iii) under microwave 
conditions in DCB. A comparison between the literature findings and our CF rDA 
results is presented in Figure 6. These findings validate that the proposed CF rDA 
protocol is superior to the existing conventional batch technologies. As shown, 
pyrimidinone derivatives 39–44 were gained in excellent yields and shorter reaction 
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times when compared to the corresponding batch processes, especially in case of 
compound 23c, which did not undergo decomposition under batch conditions.  
 
Figure 6. Comparison in terms of isolated yields between CF rDA and different batch 
methods for the synthesis of pyrimidinone derivatives 39–44. (Lit: literature data115,172-176) 
Our next effort was to test the viability of the CF rDA protocol with more complex 
fused pyrimidinone moieties 24–29, which appeared to be a challenge to the CF rDA 
method to provide retrodiene products 47–52. Therefore, by screening different polar 
and aprotic solvents, MeCN or MeOH was preferred over nonpolar solvents, especially, 
when high concentrations were employed. Therefore, we opted for MeCN as a suitable 
and benign solvent and used it subsequently to study the effect of temperatures. It was 
quickly established that temperatures of 220–250 °C gave full conversions without the 
unwanted thermal degradation of the rDA products within 15 min residence time, 
whereas lower temperatures significantly slowed down the reactions. With these 
conditions in hand, tetracyclic pyrrolo[1,2-a]quinazolinones 24–26 and pentacyclic 
isoindolo[1,2-a]quinazolinones 27–29 were dissolved in MeCN and after 5 min of 
stirring at ambient temperature, the homogeneous mixtures were introduced into the 
reactor through an HPLC pump (Figure 4). Heating the mixtures at 220 °C or 250 °C 
led to the expected pyrrolopyrimidinones 47–49 (Table 3, entries 1–3) and 
pyrimidoisoindoles 50–52 (Table 3, entries 4–6) with a residence time of 15 min in 
isolated yields over 90% after purification via column chromatography. These results 
match the parent batch experiments in terms of isolated yields.177,178 
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Table 3. Results with the use of the CF rDA process for the synthesis of pyrimidinone 
47–52 under the optimised reaction conditions. 
4.1.3. Testing the capacity of the CF rDA protocol for providing NCE 
Herein, we turned our attention to investigate chemical skeletons, which have not 
been subjected to rDA reactions previously through conventional batch approaches. 
Hence, spiroquinazolinone derivatives 30–38 were selected to be tested under CF rDA 
Entry 
Starting 
material 
CF rDA Product 
CF optimised reaction conditions 
Solvent 
Temp 
[°C] 
Residence     
time [min] 
Yielda 
[%] 
1 24 
 
MeCN 
250 15 98 
2 25 
 
220 15 97 
3 26 
 
220 15 95 
4 27 
 
220 15 98 
5 28 
 
220 15 96 
6 29 
 
250 15 97 
a Isolated yield. 
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conditions. We started our study by optimizing the operating parameters. Namely, 
spiroquinazolinone 30–38 were first dissolved in MeCN and loaded into the CF reactor 
at different temperatures based on their melting points with respect to their 
stereochemistry (diendo versus diexo condensation). The initial assessment of the 
obtained results revealed that compounds 30–38 underwent thermal decomposition 
affording only moderate conversions to retrodiene products 53–55 with significant 
amounts of rDA degradation products. Following these disappointing results, we 
decided to optimize further our operating parameters. After screening different solvents 
we found that a mixture of toluene and MeOH (4:1 v/v) worked best to give new 2-
spiropyrimidin-4-ones 53–55. In an illustrative procedure, a solution of diexo-
methylene-bridged 2-spiroquinazolinone 30 in toluene/MeOH (4:1) was introduced into 
the heated 304 stainless steel coil reactor at 240 °C with a residence time of 60 min 
(Table 4, entry 1). The residence time was increased by utilizing longer coil in order to 
further improve the conversion. Under these conditions, 1,5-diazaspiro[5.5]undec-3-en-
2-one (53) was isolated in an increased yield of 73%. Furthermore, we wanted to 
investigate the CF rDA effect on diendo-isomer 31 in the hope that we could further 
increase the yield of 53. Since diendo-stereoisomers are thermally unstable compared to 
their diexo-analogues, they more easily underwent the rDA reaction. Thus, 31 was 
treated under the same conditions (Table 4, entry 2). With a residence time of 60 min 53 
was obtained in almost the same yield (75%) as demonstrated previously in the case of 
its diexo-isomer 30. This result shows that a change in stereochemistry does not have 
any significant effect on the reaction yield. Subsequently, we headed towards the 
epoxy-bridged 2-spiroquinazolinone 32 with the expectation that removal of the furan 
ring as a diene at lower temperatures would be much easier than that of 
cyclopentadiene. This may improve the yield by increasing the conversion and 
minimizing the quantity of degradation products because of the lower temperatures 
used. Therefore, we utilised a temperature of 150 °C. Accordingly, complete conversion 
could be obtained at 60 min residence time and the desired spiro-compound 53 was 
isolated with a yield of 95% (Table 4, entry 3).  
Encouraged by these promising results, a series of experiments were then undertaken 
to gain a better understanding of the thermally-driven CF rDA effect on the 
transformation of other spiroquinazolinone scaffolds. Accordingly, we treated 
compounds 33–38 under the CF reaction conditions described above. Benzylpiperidine 
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derivative 54 and adamantane 55 were obtained in good yields of 92% and 86%, 
respectively (Table 4, entries 6, 9). Importantly, the yields obtained from the epoxy-
bridged spiro-compounds were always higher than those for the methylene-bridged 
analogues. 
Table 4. Results with the use of the CF rDA process for the synthesis of 
spiropyrimidinones 53–55 as NCE. 
In line with our previous findings, we wanted to explore whether spirocompounds 
30–38 undergo thermal decomposition under conventional batch conditions. For this 
purpose, we envisaged to adopt two different batch methods. The parent method 
included a simple heating of spiroquinazolinone derivatives 30–38 at their melting 
points, whilst in the second method the rDA reactions were performed under microwave 
conditions. To this end, in solvent-free experiments, compounds 30–38 were heated at 
around 10 °C above their melting points. Although HPLC–MS analysis showed the full 
degradation of starting materials 30–38, rDA products 53–55 were not detected in any 
case. In contrast, when microwave irradiation was applied on compounds 30–38, 
slightly higher than medium or no conversions to retrodiene products 53–55 were 
found. 
 
Entry 
Starting 
material 
CF rDA Product 
CF optimised reaction conditions 
Solvent 
Temp 
[°C] 
Residence     
time [min] 
Yielda  
[%] 
1 30 
 
Toluene
/MeOH 
(4:1) 
240 60 73 
2 31 240 60 75 
3 32 150 60 95 
4 33 
 
240 60 53 
5 34 240 60 70 
6 35 150 60 92 
7 36 
 
240 60 51 
8 37 240 60 57 
9 38 150 60 86 
a Isolated yield. 
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The best MW-promoted cycloreversion for the synthesis of compounds 53–55 was 
achieved with epoxy-spiroquinazolinone 32, 35 and 38 irradiated in DCB at 180 °C for 
30 min. These conditions afforded isolated yields of 78%, 89%, and 78%, respectively 
(Figure 7). The obtained values are lower than those found in the CF rDA process 
(Table 4, entries 3, 6, 9). A thorough comparison for spiropyrimidinones 53–55 
prepared by the batch and the CF process is shown in Figure 7. These data clearly 
demonstrate the superiority of the CF technology compared to the existing conventional 
batch methods. 
 
Figure 7. Comparison in terms of isolated yields between CF rDA and microwave 
processes for the synthesis of new spiropyrimidinone chemical scaffolds 53–55. 
MW-induced rDA (orange); CF rDA (blue). 
4.1.4. Investigation of the scope and applicability extent of the CF rDA method 
To establish the range of applicability of our CF rDA process, the syntheses of 
enantiomerically pure pyrrolo[1,2-a]pyrimidine 49 and pyrimido[2,1-a]isoindole 50 
through rDA reaction under CF conditions were undertaken (Scheme 16). The source of 
chirality, (1R,2R,3S,4S)-3-amino-N-methylbicyclo[2.2.1]hept-5-ene-2-carboxamide  
[(–)-15f] was prepared by known literature protocols.185 In a stereocontrolled ring-
closing reaction, (–)-15f was reacted with 3-oxo-3-(p-tolyl)propanoic acid to afford 
single diastereoisomer (+)-26 in good yield (82%). The ready loss of cyclopentadiene 
through the CF rDA protocol at 220 °C resulted in (S)-1-methyl-8a-(p-tolyl)-1,7,8,8a-
tetrahydropyrrolo[1,2-a]pyrimidine-2,6-dione enantiomer (+)-49 in high yield (97%) 
with an ee value of 97%. When carboxamide (–)-15f was treated with 2-formylbenzoic 
acid, pentacyclic isoindolo[1,2-a]quinazolinone (+)-27 was formed and then isolated in 
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yield of 83%. The CF-induced thermolysis of (+)-27, at 250 °C, gave the expected (S)-
1-methyl-1,10b-dihydropyrimido[2,1-a]isoindole-2,6-dione [(–)-50] within a residence 
time of 15 min at full conversion, in yield of 97% and with an ee value of 98%. 
 Scheme 16. The syntheses of enantiomerically pure pyrrolo[1,2-a]pyrimidine 
49 and pyrimido[2,1-a]isoindole 50 through CF rDA reaction. 
4.2. Continuous-flow enabled efficient patterning of β-peptide foldamers  
Efficient design of the secondary structures of the peptidic foldamers is a great 
challenge. For assessment of the effect of the new structural elements on β-peptide 
conformation, we examined the helix-forming property of oligomers containing 
enantiomeric bicyclic β-amino acid residues and their chemical derivatives.[IV] To this 
end, pentamers made of [1R,2R]-ACHC building blocks possessing an enantiomer of 
bicyclic residue in the middle of the peptide chain were assembled by revolutionary CF-
SPPS (Figure 5) synthetic methods and illustrated in Scheme 17. As bridged residues, 
enantiomers of diexo-3-aminobicyclo[2.2.1]hept-5-ene-2-carboxylic acid (diexo-
ABHEC) and diexo-3-amino-7-oxabicyclo[2.2.1]hept-5-ene-2-carboxylic acid (diexo-
AOBHEC) were used to compare the ability of folding regarding the configuration and 
study the effect of an oxygen-bridged residue on self-organisation. The reference 
secondary structures formed by the homochiral sequences are known. For example, the 
homochiral homooligomers of [1R,2R]-ACHC facilitate an H14 helix,135 while diexo-
ABHEC enantiomer residues promote a chain dependent right and left handed 
consecutive 6-strands.186 In contrast, with alternating backbone configuration of 
oligomers containing [2S,3R]/[2R,3S]-ABHEC enantiomer units, with protected or free 
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at both ends, they are not capable of helix formation; their secondary structures are a 
bend-strand187 or a circle-like fold.188 Note that diexo-AOBHEC units adopt an 8-
membered hydrogen-bonded ring conformation.189 
 
Scheme 17. The investigated structures possessing an enantiomeric bicyclic residue in 
the middle of the peptide chain. 
 
To investigate the effect of Z-dehydro-β-alanine on self-organisation, compounds 
56–59 containing diexo-ABHEC and diexo-AOBHEC units were subjected to the 
CF rDA protocol. As an illustration, solutions of β-peptide homooligomers 56–59 
dissolved in MeOH were introduced into the CF rDA reactor (Figure 4). Heating the 
mixtures of 57 and 59 at 150 °C or 56 and 58 at 230 °C led to the expected oligomer 60 
within a residence time of 14 min, with full conversion (Scheme 18) and in yields over 
90% after purification by RP-HPLC techniques. These results probe the versatility of 
the CF rDA protocol by providing distinct peptidic structures. 
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Scheme 18. The synthesis of oligomer 60 through CF rDA reaction. 
As a next step, we studied the folding behaviour of peptide 61 containing saturated 
β-alanine by changing the third unit from Z-dehydro-β-alanine to β-alanine unit. Thus, 
we intended to further capitalize on the CF methodology benefits for the preparation of 
peptide 61 (Scheme 19). Accordingly, CF rDA product 60 was saturated in an H-Cube® 
CF hydrogenation reactor on a 10% Pd/charcoal catalyst to afford oligomer 61 in good 
yield (95%). 
 
Scheme 19. The synthesis of oligomer 61 through CF hydrogenation reaction. 
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Peptides 56–61 were analysed by HPLC–MS and characterised through the use of 
different NMR methods. The analytical HPLC chromatograms of foldamers in 
diastereomeric relation, e.g. 56 vs. 58 and 57 vs. 59 showed drastic differences. 
Foldamers 56 and 57 possess substantially higher retention time than those observed for 
58 and 59. This finding suggests that 56 and 57 are more hydrophobic than 58 and 59. 
According to previous results,144 the ordered helical structure is more hydrophobic since 
the amide bonds are in the centre of the structure and only the hydrophobic side-chains 
interact with the chromatographic system. Helix formation, consequently, might be 
anticipated for compounds 56 and 57. 
4.3. Stereochemical discrimination in the synthesis of β-peptide oligomers: origin 
of homochirality 
Homochirality is an inherent property of vital polymers, i.e., peptides, proteins, 
RNA, DNA, as well as oligo- and polysaccharides.190-192 It is still not clear whether 
homochirality is a result of an autocatalytic procedure or if it originates from 
extraterrestrial optically active non-racemic mixtures. For the natural α-peptides, 
numerous assays have been carried out to clarify the origin of this phenomenon, mainly 
by studying the stereochemical discrimination in their synthesis.193-195 In the case of -
peptide foldamers, however, the formation of the homochiral peptide from a racemic 
starting mixture is still ambiguous compared to the natural α-peptides. Herein we 
proved, that the stereochemical discrimination towards the homochiral oligomers 
manifests for β-peptides too, akin to the biological homochirality of natural polymers.[I] 
The effect of secondary structures and the side-chain size and length on the 
stereochemical course of the homochiral oligomer formation was investigated. Thus, β-
peptide foldamers containing various cyclic side-chains and possessing different 
secondary structures were selected for the examination of diastereo-discriminative 
peptide coupling with chain lengths varying from trimer to hexamer. As a reference, the 
natural α-L-leucine (L-Leu) oligopeptides were selected. The investigated peptide 
structures were assembled by CF-SPPS (Figure 5) and are shown in Scheme 20. 
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Scheme 20. The investigated structures possessing five- and six-membered side-chains 
and cis or trans relative configuration. 
Oligomers 62–65 are composed of [1R,2R]-2-aminocyclopentanecarboxylic acid 
([1R,2R]-ACPC) building blocks and are known to form H12 helix.136 As a next step, 
the five-membered cyclic side-chains were changed for six-membered cyclohexane 
rings (compounds 66–69), while retaining the same stereochemistry. That is the 
oligomers were constructed from [1R,2R]-ACHC residues and they form an H14 
helix.135 To investigate the effect of a strand structure, oligomers 70–73 created from 
[1S,2R]-ACHC were assembled too. Homochiral homooligomers made from cis-β-
amino acids are known to form strand structure.22,196 As a control structure, 
homooligomeric α-peptides 74–77 composed of L-Leu were synthesized too. The 
isobutyl side-chain was selected in accordance with the β-amino acids described above, 
since only aliphatic side chains were tested. 
Having the desired peptide structures in hand, the stereochemical discrimination 
property of these peptides was tested by means of the solution-phase peptide coupling 
technique as demonstrated in Scheme 21 with the example of oligomers built from 
[1R,2R]-ACHC. The purified peptides (66–69) were dissolved in the mixture of 
CH2Cl2/DMF (2:1) and 10 equiv. of Boc-protected racemic amino-acid (±)-78 was 
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coupled by the utilisation of DIC and HOBt coupling agents and the mixture was stirred 
for 48 h. Importantly, the effect of water on the stereochemical discrimination was 
investigated too, since it is known to be a crucial factor.193,194 Thus, the reactions 
described previously were performed in the solvent system CH2Cl2/DMF/water (2:1:1) 
in 48 h. The solvents were removed in vacuo, Boc deprotection was carried out by TFA 
treatment and the two diastereomeric products were first lyophilised and then analysed 
by means HPLC–MS technique. The homochiral chain elongated reference compounds 
were always synthesized independently and the heterochiral diastereomers were 
identified by the HPLC–MS chromatogram. 
Scheme 21. Chain elongation of β-peptides 66–69 with racemic (±)-78 yielding 
diastereomers 79–82 (heterochiral) and 83–86 (homochiral) shown by the example of 
[1R,2R]-ACHC residue. 
Herein two HPLC–MS chromatograms are presented for the coupling of Boc-
protected racemic amino-acid (±)-78 with trimer 66 in the absence (Figure 8a) and 
presence (Figure 8b) of water. These results revealed that the formation of the 
homochiral homooligomer 83 was predominant when water was used as a co-solvent in 
the diastereo-discriminative coupling. 
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Figure 8. HPLC–MS chromatograms of the coupling of racemic (±)-78 with trimer 66 
(a) in the absence and (b) in the presence of water. 
Based on the area integrals of the homochiral and heterochiral peptides, the 
diastereomeric excess (de) of the reaction was calculated for all peptides both in the 
presence and in the absence of water. The de values are shown in Figure 9 in a chain-
length-dependent manner. 
 
Figure 9. Diastereomeric excess (de) values obtained for 62–65 (thin solid line), 66–69 
(thick solid line), 70–73 (thin dashed line), 74–77 (thick dashed line) in absence (a) and 
in presence of water (b) as a function of chain-length (n). 
In the absence of water, a strong tendency towards the homochiral structures was 
observable for peptides containing the [1R,2R]-ACPC unit (62–65). A slight decrease in 
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selectivity was found as a function of chain length. The situation is completely different 
for the oligomers composed of [1R,2R]-ACHC (66–69), which contain a more bulky 
side-chain. The selectivity changed, the formation of the heterochiral product became 
favoured (Figure 8a), and a nice chain-length-dependent correlation was found. It is 
important to note that a simple change in the side-chain caused a drastic difference in 
the stereochemical discrimination properties of β-peptides. To investigate the effect of 
cis relative configuration, compounds containing [1S,2R]-ACHC (70–73) were also 
studied. Again, a definite tendency was observed towards the homochiral oligomers. 
The chain length did not significantly alter the de value. As a reference, α-peptides 
composed of L-Leu were investigated. The diastereoselectivity showed a clear chain-
length-dependent manner and the homochiral product was favoured. Importantly, the 
chain elongation of the trimer L-Leu showed only very minor diastereo-differentiation. 
In general, the presence of water enhanced the selectivity toward the formation of 
homochiral homooligomers. In the case of peptides built of [1R,2R]-ACPC, de values 
increased compared to those formed in non-aqueous experiments and a clear chain-
length-dependent increase could also be observed. The most dramatic difference 
compared to the experiment performed without water can be observed for oligomers 
comprising [1R,2R]-ACHC. The selectivity changed to the opposite direction and 
homochiral compounds were profoundly formed during the coupling of the Boc-
protected racemic [1R,2R]-ACHC (Figure 8b). In this case, a more dominant chain-
length-dependent fashion can be observed and, importantly, the diastereoselective chain 
elongation of the hexamer reached a de of almost 90%. The effect of cis relative 
configuration was also investigated in the presence of water. The results indicate again 
the profound formation of the homochiral oligomer. Interestingly, de values decreased 
to some extent as a function of chain length. The reference L-Leu oligomers preferred 
the incorporation of the homochiral amino acids in a chain-length-dependent manner. 
Nonetheless, water, in general, increased the de values compared to the results of the 
water-free experiments. 
To understand the effect of water on the diastereoselective chain-elongation reaction, 
the effect of water on the foldameric systems itself should be considered. Foldameric 
systems are known to show secondary structure-dependent self-association with water 
as the solvent.22,23 Helical structures self-associate into vesicles, whereas strand 
structures form nano-sized fibrils as shown in Figure 10, reported by transmission 
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electron microscopy (TEM) measurements. It has been reported that the self-association 
of peptides is a crucial factor behind biological homochirality.193,194 
 
 
Figure 10. TEM images of (a) the amyloid-like fibrils formed by the heptamer [1R,2S]-
ACPC (strand structure); (b) the vesicles obtained for [1R,2R]-ACHCn for i) 67, ii) 68, 
and iii) 69, vi) the multilamellar vesicles after sonication of 68.22,23 
Consequently, theoretical calculations were performed to investigate the effect of 
self-association of β-peptides on stereochemical discrimination. Oligomer 68 containing 
[1R,2R]-ACHC selected as an example showed the most dramatic water-dependent 
diastereo-discrimination. DFT calculations were carried out at the OLYP/tz2p level of 
theory and the transition states were calculated for the systems composed of Boc-
protected [1R,2R]- and [1S,2S]-ACHC hydroxybenzotriazole esters and oligomer 67. 
The structure of the latter was previously optimised in the form of an H14 helix. The 
reason for selecting β-peptide 67 is that it forms a helical structure with the shortest 
chain length, which is the optimum structure for quantum-chemical calculations with 
acceptable calculation times. Solvent effects were taken into account by means of the 
COSMO solvent model utilizing the permittivity of chloroform and water. The 
calculated relative barrier energies are shown in Table 5. 
Table 5. Relative barrier energies (in kcal mol-1) for the transition state of the chain 
elongation 67 in water and chloroform. 
Solvent Homochiral chain elongation Heterochiral chain elongation 
Chloroform 2.4 1.0 
Water 4.8 0.0 
The reaction barrier of the heterochiral construct was found to be lower than those 
for the homochiral one in both solvents. Consequently, the simplified model system 
cannot reproduce the changes in the trends caused by the absence or presence of water. 
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However, investigating the 3D structure of the homo- and heterochirally elongated 
compounds, self-association might increase geometrical strain.  
Molecular modelling was carried out to further examine the effect of self-association 
on the stereochemical discrimination in the chain elongation of β-peptides. First a 
membrane segment was constructed and optimised by utilizing the MMFF94 force 
field. The assembly is shown in Figure 11a. For this purpose, oligomer 68 was selected, 
as it has been reported to form solely an H14 helix.  
 
Figure 11. a) Molecular model for the vesicular membrane segment formed of 68;  
b) The incorporation of the heterochirally chain-elongated construct (grey-coloured ball 
and stick representation) into the membrane. The clashes of the side-chains are depicted 
by the overlapping of the space-filling model of the involved residues.[I] 
Our effort to perform similar density functional investigations and calculate the 
height of the barrier was not successful, because of the size of the systems. However, 
hetero- and homo-chirally elongated oligomers were merged into the membrane. For the 
heterochiral constructs, a clear collision was found between the helices of oligomer 68 
building the membrane segment and the investigated compound shown in Figure 11b. 
This interaction hinders and blocks the heterochiral chain elongation and, consequently, 
the formation of homochiral oligomers is favoured. 
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SUMMARY 
Novel, sustainable flow-based synthetic methodology was implemented for the 
synthesis of racemic and enantiomerically enriched tricyclic and tetracyclic fused 
pyrimidinones as valuable NCE and precursors of a series of pharmacologically active 
materials through the rDA reaction. The design of the reactor enabled accurate control 
of both residence time and reaction temperature.  
In the first attempt for testing the capacity of the proposed CF rDA protocol, HPLC–
MS measurements revealed full conversions of 16–23 to the desired pyrimidinones 39–
44, whereas only a moderate conversion of 23c to 44 was observed. In the case of 
compounds 16–23 mainly retrodiene decomposition occurred through the splitting-off 
of cyclopentadiene or cyclohexadiene, since these compounds possess rings with a 
quasi-aromatic character. The stereochemistry (diendo versus diexo condensation) of 
the starting pyrimidinones (16, 17, 22 and 23) has no significant effect on reaction 
yields. By using this safe, stable and scalable flow process, pyrimidinones 39–44 were 
synthesized in high purities. 
As a further investigation on the ability of the CF rDA approach, the synthesis of 
more complex enantiomeric and racemic fused pyrimidinone derivatives 
pyrrolopyrimidinones (47–49), pyrimidoisoindoles (50–52), and spiropyrimidinones 
(53–55) were tested. The preparation of intermediates 24–38 through domino ring 
closure or spirocyclisation under CF conditions was achieved in high yields. This 
protocol represents an alternative time-efficient route. In the case of pyrrolo[1,2-
a]quinazoline and isoindolo[2,1-a]quinazoline derivatives 24–29, HPLC–MS 
measurements revealed full conversions to the desired pyrrolopyrimidinones and 
isoindolopyrimidinones 47–52. In contrast, only moderate conversions to new 
spiropyrimidinones 53–55 were observed for methylene-bridged spiroquinazolinones 
30, 31, 33, 34, 36, and 37. It is interesting that epoxy-bridged spiroquinazolinones 32, 
35 and 38, in which an oxygen atom has been introduced at position C-7 of the β-
aminonorbornene carboxamide skeleton, gave retrodiene products 53–55 in almost 
quantitative yields. 
It is important to note, that the CF reactor set-up ensured enhanced safety and 
afforded higher yields than those found with batch and microwave processes. These 
results could be achieved through careful reaction parameter optimisation. It is 
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particularly true for 23c, 33, 36 and 37, which were unreactive (0% yield) under batch 
conditions, in contrast to yields of 30–57% obtained when employing the CF rDA 
protocol. Thus, this method proved its ability to provide new, otherwise inaccessible, 
chemical entities (44, 45 and 53–55) in good yields with short processing times. 
Moreover, the method allowed the replacement of high-boiling and toxic solvents, e.g., 
CB or DCB, which are commonly employed in batch process by less harmful, 
environmentally benign solvents such as toluene, MeCN, MeOH, and EtOH. 
Furthermore, the CF methods allowed the efficient construction of six new β-peptide 
systems (56–59) built from [1R,2R]-ACHC residues containing enantiomeric bicyclic 
residue as the third building block. Upon investigating their helical folding ability, we 
proved the versatility of the CF rDA protocol, which provided distinct peptidic 
structures. Namely, oligomer 60 was obtained in high yields, when 56–59 were treated 
under CF rDA conditions. β-Alanine-containing peptide 61 was afforded upon 
subjecting 60 to the CF hydrogenation reactor. 
 We further proved that biological homochirality as an inherent property is also 
occurring with unnatural compounds like β-peptide foldamers. The phenomenon was 
investigated by means of diastereoselective amino acid coupling. β-Peptide oligomers 
composed of either cis or trans alicyclic β-amino acids showed a tendency towards the 
homochiral constructs. Theoretical calculations indicated that water plays a crucial role 
in this phenomenon through the induction of self-association. In all cases, water 
enhanced the diasetereoselectivity towards the homochiral oligomers by promoting 
biological homochirality. 
The results collected and discussed in this PhD thesis might be readily extended to 
the preparation of other synthetically important building blocks requiring harsh 
conditions in batch methods. The simple, efficient and scalable production implemented 
with a short processing time might open up new horizons for a potential CF industrial 
synthesis of heterocycles and β-peptides. 
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Homochirality of b-Peptides: A Significant Biomimetic
Property of Unnatural Systems
Istvn M. Mndity,[a] Imane Nekkaa,[a] Gbor Paragi,[b] and Ferenc Flçp*[a, c]
Homochirality, an interesting phenomenon of life, is mainly an
unresolved problem and was thought to be a property of
living matter. Herein, we show that artificial b-peptides have
the tendency toward homochiral diastereoselective chain elon-
gation. Chain-length-dependent stereochemical discrimination
was investigated in the synthesis of foldamers with various
side chains and secondary structures. It was found that there is
a strong tendency toward the synthesis of homochiral oligo-
mers. The size of the side chain drastically influenced the selec-
tivity of the stereodiscriminative chain-elongation reaction. It is
noteworthy that water as the co-solvent increases the selectivi-
ty. Such behavior is a novel fundamental biomimetic property
of foldamers with a potential of future industrial application.
Homochirality is an inherent property of vital polymers, for ex-
ample, peptides, proteins, RNA, DNA, as well as oligo- and
polysaccharides.[1] It is still not clear whether homochirality is
a result of an autocatalytic procedure[2] or if it originates from
extraterrestrial optically active non-racemic mixtures.[3] Numer-
ous investigations have been carried out by various research
groups to investigate the origin and role of this phenomen-
on.[1c,4] In the case of peptides, mainly the stereochemical dis-
crimination in their synthesis has been investigated. For exam-
ple, a racemate of activated amino acids was reacted with
a given enantiomerically pure amino acid or peptide chain.
The results reveal a strong tendency for the formation of ho-
mochiral sequences.[5] This effect is even more dominant when
water is utilized as a co-solvent.[5a] In the case of self-templated
peptide fragment coupling, again, homochiral compounds are
formed.[6] On the other hand, when dipeptides were created,
heterochiral sequences appeared.[7] In the case of peptides
containing strongly structure-promoting a,a-disubstituted
amino acid, the formation of heterochiral sequences is favored
when large and bulky side chains are utilized.[8] However, for
smaller side chains, the synthesis of homochiral peptides is
preferred.[9] For similar sequences, helicity alone can govern
the direction of enantioselectivity. For example, P-helices favor
the incorporation of l-amino acids, whereas M-helices prefer
the coupling of the d-enantiomer.[10]
Foldamers are artificial self-organizing biomimetic poly-
mers.[11] These systems have a strong tendency to form highly
stable and versatile secondary structures, for example, helices,
strands, turns, and so on.[11g,12] Foldamers have numerous bio-
medical activities.[13] They are antibacterial amphiphills,[14] cell
and membrane penetrating peptides,[15] anti-Alzheimer com-
pounds,[16] and effectively modulate protein–protein interac-
tions.[17] Based on this fact, they are nowadays considered as
proteomimetics.[13a] Some of the most thoroughly investigated
foldamers are the b-peptides,[11d–f,18] which possess additional
biomimetic properties akin to natural a-peptides including hi-
erarchical self-organization,[19] conformational polymorphism,
and real folding reactions.[20]
Herein, we show that stereochemical discrimination towards
the homochiral oligomers manifests for b-peptides too, akin to
the biological homochirality of natural polymers. The phenom-
enon can be observed for various b-peptides with different
secondary structures, side-chain shape, and chain length.
b-Peptide foldamers containing various cyclic side chains
and possessing different secondary structures were selected
for the examination of diastereo-discriminative peptide cou-
pling with chain lengths varying from trimer to hexamer. As
a reference, a-l-leucine homooligopeptides were selected. The
investigated structures are shown in Scheme 1.
Oligomers 1–4 are composed of [1R,2R]-trans-2-aminocyclo-
pentanecarboxylic acid ([1R,2R]-trans-ACPC) building blocks
and they are known to form H12 helices.[11b] As a next step, for
compounds 5–8, the five-membered cyclic side chains were
changed for a six-membered cyclohexane ring, while retaining
the same stereochemistry. These oligomers were constructed
from [1R,2R]-trans-2-aminocyclohexanecarboxylic acid ([1R,2R]-
ACHC) residues.[11a] The formed secondary structure is a H14
helix. To investigate the effect of a strand structure, oligomers
created from [1S,2R]-cis-ACHC were also assembled (b-peptides
9–12). Homochiral homooligomers made from cis-b-amino
acids are known to form strand structures.[19,21] This fact is fur-
ther supported by a stereochemical patterning approach,
which declares that b-peptides possessing different stereo-
chemistry on the two sides of an amide bond form a strand
structure.[12b]
As control structures, homooligomeric a-peptides composed
of l-Leu were synthesized too (13–16). The isobutyl side chain
[a] Dr. I. M. Mndity, I. Nekkaa, Prof. Dr. F. Flçp
Institute of Pharmaceutical Chemistry
University of Szeged
Eçtvçs u. 6, 6720 Szeged (Hungary)
E-mail : fulop@pharm.u-szeged.hu
[b] Dr. G. Paragi
MTA-SZTE Supramolecular and Nanostructured Materials Research Group
Dm tr 8, 6720 Szeged (Hungary)
[c] Prof. Dr. F. Flçp
Research Group of Stereochemistry of the Hungarian Academy of Sciences
Dm tr 8, 6720 Szeged (Hungary)
Supporting Information for this article can be found under:
https://doi.org/10.1002/open.201700078.
 2017 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA.
This is an open access article under the terms of the Creative Commons
Attribution License, which permits use, distribution and reproduction in
any medium, provided the original work is properly cited.
ChemistryOpen 2017, 00, 0 – 0  2017 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim1 &
These are not the final page numbers! 
DOI: 10.1002/open.201700078
was selected in accordance with the b-amino acids described
above, as only b-peptides comprising aliphatic side chains
were tested.
The peptides were assembled by utilizing highly efficient
continuous-flow solid-phase peptide synthesis technology de-
veloped in our laboratory.[22] The technology allows the con-
struction of various peptides by using very low, generally 1.5-
fold, amino-acid equivalents. The peptides were elongated in
the instrument, and the products were cleaved and purified
through regular reversed-phase HPLC methodology.
The stereochemical discrimination properties of the b-pep-
tides were tested by means of a solution-phase peptide-cou-
pling technique. The purified peptides were dissolved in a 2:1
mixture of dichloromethane (DCM) and N,N-dimethylforma-
mide (DMF). Subsequently, 10 equivalents of the tert-butyloxy-
carbonyl (Boc)-protected racemic amino acid was coupled by
using N,N’-diisopropylcarbodiimide (DIC) and hydroxybenzo-
triazole (HOBt) coupling agents. The reaction time was 48 h.
Importantly, the effect of water on the stereochemical discrimi-
nation was also investigated, as it is known to be a crucial fac-
tor.[5a,6] Thus, the reactions described above were performed in
the solvent system DCM/DMF/H2O 2:1:1 with a reaction time
of 48 h. The solvents were removed in vacuo and Boc depro-
tection was carried out by TFA treatment. Finally, the product
was lyophilized and the raw material was analyzed by using
HPLC–MS. The complete procedure is shown in Scheme 2 with
the example of oligomers built from trans-ACPC. The homochi-
ral chain-elongated reference compounds were always synthe-
tized independently and the heterochiral diastereomers were
deduced from the HPLC–MS chromatogram.
Based on the area integrals of the homochiral and heterochi-
ral peptides, the diastereomeric excess (DE) of the reaction was
calculated for all peptides in both the presence and the ab-
sence of water. The DE values are shown in Figure 1 in a chain-
length-dependent manner.
In the absence of water, a strong tendency towards the ho-
mochiral structures was observable for peptides containing the
[1R,2R]-trans-ACPC unit (1–4). A slight decrease in selectivity
was found as a function of chain length. The situation is com-
pletely different for the oligomers composed of [1R,2R]-trans-
ACHC (5–8), which contain a more bulky side chain. The selec-
tivity changed, the formation of the heterochiral product
became favored, and a nice chain-length-dependent correla-
tion was found. A change in selectivity towards the heterochi-
ral sequences in a stereo-discriminative chain elongation was
observed for peptides composed of a,a-disubstituted amino
acids with large bulky side chains.[9] A simple change in the
side chain caused a drastic difference in the stereochemical
discrimination properties of b-peptides. To investigate the
effect of cis relative configuration, compounds containing
[1S,2R]-cis-ACHC (9–12) were also studied. Again, a definite
tendency was observed towards the homochiral oligomers.
The chain length did not significantly alter the DE value. As
Scheme 1. The investigated structures possessing five- and six-membered
side chains and cis or trans relative configuration.
Scheme 2. The chain elongation of a b-peptide with a Boc-protected race-
mic amino acid yielding two diastereomers shown by the example of the
trans-ACPC residue.
Figure 1. DE values obtained for 1–4 (thin solid line), 5–8 (thick solid line),
9–12 (thin dashed line), and 13–16 (thick dashed line) in the absence (a)
and in the presence of water (b) as a function of chain length.
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a reference, a-peptides composed of l-Leu were investigated.
The diastereoselectivity showed a clear chain-length-depen-
dent manner and the homochiral product was favored. Impor-
tantly, the chain elongation of the trimer l-Leu showed only
very minor diastereo-differentiation.
In general, the presence of water enhanced the selectivity
toward the formation of homochiral homooligomers. In the
case of peptides built of [1R,2R]-trans-ACPC, DE values in-
creased compared to those formed in non-aqueous experi-
ments and a clear chain-length-dependent increase could also
be observed. The most dramatic difference compared to the
experiment performed without water can be observed for olig-
omers comprising [1R,2R]-trans-ACHC. The selectivity changed
to the opposite direction and homochiral compounds were
profoundly formed during the coupling of the Boc-protected
racemic trans-ACHC. In this case, a more dominant chain-
length-dependent fashion can be observed and, importantly,
the diastereoselective chain elongation of the hexamer
reached a DE of almost 90%. The effect of cis relative configu-
ration was also investigated in the presence of water. The re-
sults indicate again the profound formation of the homochiral
oligomer. Interestingly, DE values decreased to some extent as
a function of chain length. The reference l-Leu oligomers pre-
ferred the incorporation of the homochiral amino acids in
a chain-length-dependent manner. Nonetheless, water, in gen-
eral, increased the DE values compared to the results of the
water-free experiments.
To understand the effect of water in the diastereoselective
chain-elongation reaction, the effect of water on the foldamer-
ic systems itself should be considered. Foldameric systems are
known to show secondary structure-dependent self-association
with water as the solvent.[19,20] Helical structures self-associate
into vesicles, whereas strand structures form nano-sized fibrils.
It has been reported that the self-association of peptides is
a crucial factor behind biological homochirality.[5a,6] Conse-
quently, we turned to investigate the effect of self-association
of b-peptides on the stereochemical discrimination by means
of theoretical calculations. Oligomer 7, containing trans-ACHC,
has been selected as an example, as it showed the most dra-
matic water-dependent diastereo-discrimination.
Having a draft picture about the reaction barriers or possible
steric hindrances, DFT calculations were carried out at the
OLYP/tz2p level of theory.[23] This method can provide accepta-
ble geometries or reaction barriers for organic compounds.[24]
Transition states were calculated for the systems composed of
Boc-protected [1R,2R]- and [1S,2S]-trans-ACHC hydroxybenzo-
triazole ester and oligomer 6. The structure of the latter was
previously optimized in the form of a H14 helix. The reason for
selecting b-peptide 6 is that it forms a helical structure with
the shortest chain length,[11a] which is the optimum structure
for quantum chemical calculations with acceptable calculation
times. Solvent effects were taken into account by means of the
COSMO solvent model, utilizing the permittivity of chloroform
and water.[25] The calculated relative barrier energies are shown
in Table 1.
The reaction barrier of the heterochiral construct was found
to be lower than those for the homochiral one in both sol-
vents. Consequently, the simplified model system cannot re-
produce the changes in the trends caused by the absence or
presence of water.
However, investigating the 3D structure of the homo- and
heterochirally elongated compounds, self-association might in-
crease geometrical strain. To examine the effect of self-associa-
tion on the stereochemical discrimination in the chain elonga-
tion of b-peptides, further theoretical calculations were carried
out and first a membrane segment was constructed and opti-
mized by utilizing the MMFF94[26] force field. The assembly is
shown in Figure 2a. For this purpose, oligomer 7 was selected,
as it has been reported to form solely a H14 helix.[20]
Our effort to perform similar density functional investiga-
tions and calculate the height of the barrier was not successful,
because of the size of the systems. However, hetero- and ho-
Table 1. Relative barrier energies (in kcalmol1) for the transition state of
the chain elongation 6 in water and chloroform.
Solvent Homochiral
chain elongation
Heterochiral
chain elongation
chloroform 2.4 1.0
water 4.8 0.0
Figure 2. a) Molecular model for the vesicular membrane segment formed
of 7 (top view). b) The incorporation of the heterochirally chain-elongated
construct to the membrane (grey-colored ball-and-stick representation). The
clashes of the side chains are depicted by the overlapping of the space fill-
ing model of the involved residues.
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mochirally elongated oligomers were merged into the mem-
brane. For the heterochiral constructs, a clear collision was
found between the helices of oligomer 7 building the mem-
brane segment and the investigated compound shown in Fig-
ure 2b. This interaction hinders and blocks the heterochiral
chain elongation, and, consequently, the formation of homo-
chiral oligomers is favored.
We can conclude that the biological homochirality as a prop-
erty is also occurring with unnatural compounds, like b-pep-
tide foldamers. The phenomenon was investigated by means
of diastereoselective amino-acid coupling. b-Peptide oligomers
composed of either cis or trans alicyclic b-amino acids showed
a tendency towards the homochiral constructs. The oligomers
composed of [1R,2R]-trans-ACHC residues showed an interest-
ing property. In non-aqueous solvent systems, these com-
pounds favored the formation of the heterochiral construct ;
whereas, in the presence of water, the opposite homochiral
oligomers were preferred. Theoretical calculations indicated
that water plays a crucial role in this phenomenon through the
induction of self-association. In all cases, water enhanced the
diasetereoselectivity towards the homochiral oligomers. This
property was observed for the l-Leu-containing reference a-
peptides, further underlining the key role of water in the in-
duction of biological homochirality. It should be noted that
a relationship between the chain length and diastereoselectiv-
ity of the chain-elongation reaction might be established in
the presence of water. In the case of oligomers composed of
trans-ACPC, trans-ACHC, or l-Leu residues, the longer chain
length provided higher DE values in the presence of water. For
the strand-forming compounds containing cis-ACHC residues,
in contrast, the chain length did not drastically influence dia-
stereoselectivity. The results gained in this fundamental study
might provide the basis for industrial synthesis of b-peptides.
Experimental Section
Peptide Synthesis
Homooligomer foldamers 1–16 were synthesized by using a stan-
dard solid-phase technique utilizing fluorenylmethyloxycarbonyl
(Fmoc) chemistry. The peptide chains were elongated on TentaGel
R RAM resin (0.19 mmolg1) and the syntheses were carried out
manually on a 0.1 mmol scale. Couplings were performed with
HATU/DIPEA without difficulties. The formed peptide sequences
were cleaved from the resin with 95% trifluoroacetic acid (TFA)
and 5% H2O at room temperature for 3 h. TFA was then removed
and the resulting free peptides were solubilized in aqueous acetic
acid (10%), filtered, and lyophilized. The crude peptides were in-
vestigated by using HPLC–MS.
Diastereodiscriminative Coupling Reactions
In an illustrative procedure, solutions of peptides 1–16 (0.01 mmol)
were prepared separately with HOBt (0.12 mmol) and DIC
(0.12 mmol) in CH2Cl2/DMF (2:1) in the absence or in the presence
of water (2:1:1). Then Boc-protected racemic amino acids
(0.1 mmol) were added. The mixtures were stirred for 48 h, CH2Cl2
was removed by evaporation, and water was subsequently added
to the residue by liophilization. The product was treated with 95%
TFA and 5% water to remove Boc protecting groups. The solutions
were then stirred for 30 min, TFA was removed in vacuo, the resi-
due was diluted with water, and then lyophilized. Samples were
analyzed by using HPLC–MS.
Acknowledgements
We are grateful to the Hungarian Research Foundation (OTKA
No. K 115731). The financial support of the GINOP-2.3.2–15–
2016-00014 project is acknowledged, as well as support by the
NKP-16-4-III New National Excellence Program of the Ministry of
Human Capacities. G.P. would like to thank the Marie Curie Intra
European Fellowship and the GINOP-2.3.2–15–2016-00034 grant
for the financial support.
Conflict of Interest
The authors declare no conflict of interest.
Keywords: chirality · diastereoselectivity · foldamer ·
homochiralty · b-peptide
[1] a) W. A. Bonner, Origins Life Evol. Biospheres 1991, 21, 59–111; b) J. L.
Bada, Nature 1995, 374, 594–595; c) M. Klussmann, D. G. Blackmond, in
Chemical Evolution II,: From the Origins of Life to Modern Society, Vol.
1025, American Chemical Society, 2009, pp. 133–145.
[2] a) K. Soai, T. Shibata, I. Sato, Acc. Chem. Res. 2000, 33, 382–390; b) K.
Soai, T. Shibata, H. Morioka, K. Choji, Nature 1995, 378, 767–768.
[3] a) M. H. Engel, S. A. Macko, Nature 1997, 389, 265–268; b) B. A. McGuire,
P. B. Carroll, R. A. Loomis, I. A. Finneran, P. R. Jewell, A. J. Remijan, G. A.
Blake, Science 2016, 352, 1449–1452.
[4] a) A. Brewer, A. P. Davis, Nat. Chem. 2014, 6, 569–574; b) M. Wu, S. I.
Walker, P. G. Higgs, Astrobiology 2012, 12, 818–829; c) J. S. Siegel, Chir-
ality 1998, 10, 24–27.
[5] a) T. Li, K.-H. Budt, Y. Kishi, Chem. Commun. 1987, 1817–1819; b) S. I.
Goldberg, J. M. Crosby, N. D. Iusem, U. E. Younes, J. Am. Chem. Soc.
1987, 109, 823–830; c) T. Hitz, M. Blocher, P. Walde, P. L. Luisi, Macromo-
lecules 2001, 34, 2443–2449; d) K. Wen, L. E. Orgel, Origins Life Evol. Bio-
spheres 2001, 31, 241–248.
[6] a) M. R. Ghadiri, D. H. Lee, K. Severin, Y. Yokobayashi, Nature 1997, 390,
591–594; b) D. H. Lee, J. R. Granja, J. A. Martinez, K. Severin, M. R. Gha-
diri, Nature 1996, 382, 525–528; c) A. Saghatelian, Y. Yokobayashi, K.
Soltani, M. R. Ghadiri, Nature 2001, 409, 797–801.
[7] R. R. Hill, D. Birch, G. E. Jeffs, M. North, Org. Biomol. Chem. 2003, 1, 965–
972.
[8] a) C. Toniolo, M. Crisma, F. Formaggio, C. Peggion, Biopolymers 2001, 60,
396–419; b) C. Toniolo, E. Benedetti, Macromolecules 1991, 24, 4004–
4009; c) C. Toniolo, E. Benedetti, Trends Biochem. Sci. 1991, 16, 350–
353; d) M. De Poli, W. Zawodny, O. Quinonero, M. Lorch, S. J. Webb, J.
Clayden, Science 2016, 352, 575–580; e) B. A. F. Le Bailly, J. Clayden,
Chem. Commun. 2016, 52, 4852–4863; f) B. A. F. Le Bailly, L. Byrne, J.
Clayden, Angew. Chem. Int. Ed. 2016, 55, 2132–2136; Angew. Chem.
2016, 128, 2172–2176; g) J. E. Jones, V. Diemer, C. Adam, J. Raftery, R. E.
Ruscoe, J. T. Sengel, M. I. Wallace, A. Bader, S. L. Cockroft, J. Clayden,
S. J. Webb, J. Am. Chem. Soc. 2016, 138, 688–695.
[9] M. Crisma, A. Moretto, F. Formaggio, B. Kaptein, Q. B. Broxterman, C. To-
niolo, Angew. Chem. Int. Ed. 2004, 43, 6695–6699; Angew. Chem. 2004,
116, 6863–6867.
[10] L. Byrne, J. Sola, J. Clayden, Chem. Commun. 2015, 51, 10965–10968.
[11] a) D. H. Appella, L. A. Christianson, I. L. Karle, D. R. Powell, S. H. Gellman,
J. Am. Chem. Soc. 1996, 118, 13071–13072; b) D. H. Appella, L. A. Christi-
anson, D. A. Klein, D. R. Powell, X. L. Huang, J. J. Barchi, S. H. Gellman,
Nature 1997, 387, 381–384; c) S. H. Gellman, Acc. Chem. Res. 1998, 31,
173–180; d) D. Seebach, M. Overhand, F. N. M. Kuhnle, B. Martinoni, L.
ChemistryOpen 2017, 00, 0 – 0 www.chemistryopen.org  2017 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim4&
 These are not the final page numbers!
Oberer, U. Hommel, H. Widmer, Helv. Chim. Acta 1996, 79, 913–941;
e) P. I. Arvidsson, M. Rueping, D. Seebach, Chem. Commun. 2001, 649–
650; f) F. Flçp, T. A. Martinek, G. K. Toth, Chem. Soc. Rev. 2006, 35, 323–
334; g) T. A. Martinek, F. Fulop, Chem. Soc. Rev. 2012, 41, 687–702; h) A.
Altmayer-Henzien, V. Declerck, J. Farjon, D. Merlet, R. Guillot, D. J.
Aitken, Angew. Chem. Int. Ed. 2015, 54, 10807–10810; Angew. Chem.
2015, 127, 10957–10960; i) M. Alauddin, E. Gloaguen, V. Brenner, B. Tar-
divel, M. Mons, A. Zehnacker-Rentien, V. Declerck, D. J. Aitken, Chem.
Eur. J. 2015, 21, 16479–16493.
[12] a) T. A. Martinek, I. M. Mandity, L. Fulop, G. K. Toth, E. Vass, M. Hollosi, E.
Forro, F. Fulop, J. Am. Chem. Soc. 2006, 128, 13539–13544; b) I. M.
Mndity, E. Weber, T. A. Martinek, G. Olajos, G. K. Toth, E. Vass, F. Fulop,
Angew. Chem. Int. Ed. 2009, 48, 2171–2175; Angew. Chem. 2009, 121,
2205–2209; c) A. Altmayer-Henzien, V. Declerck, D. Merlet, J.-P. Baltaze,
J. Farjon, R. Guillot, D. J. Aitken, J. Org. Chem. 2013, 78, 6031–6039.
[13] a) I. M. Mndity, F. Flçp, Expert Opin. Drug Discovery 2015, 10, 1163–
1177; b) C. M. Goodman, S. Choi, S. Shandler, W. F. DeGrado, Nat. Chem.
Biol. 2007, 3, 252–262; c) D. Seebach, J. Gardiner, Acc. Chem. Res. 2008,
41, 1366–1375; d) W. S. Horne, Expert Opin. Drug Discovery 2011, 6,
1247–1262; e) M. Jost, J.-C. Greie, N. Stemmer, S. D. Wilking, K. Alten-
dorf, N. Sewald, Angew. Chem. Int. Ed. 2002, 41, 4267–4269; Angew.
Chem. 2002, 114, 4438–4440; f) N. Koglin, C. Zorn, R. Beumer, C. Cab-
rele, C. Bubert, N. Sewald, O. Reiser, A. G. Beck-Sickinger, Angew. Chem.
Int. Ed. 2003, 42, 202–205; Angew. Chem. 2003, 115, 212–215; g) N.
Sewald, Angew. Chem. Int. Ed. 2003, 42, 5794–5795; Angew. Chem.
2003, 115, 5972–5973; h) S. Urman, K. Gaus, Y. Yang, U. Strijowski, N.
Sewald, S. De Pol, O. Reiser, Angew. Chem. Int. Ed. 2007, 46, 3976–3978;
Angew. Chem. 2007, 119, 4050–4053; i) L. Nagel, C. Plattner, C. Budke, Z.
Majer, A. L. DeVries, T. Berkemeier, T. Koop, N. Sewald, Amino Acids
2011, 41, 719–732.
[14] a) C. Ghosh, G. B. Manjunath, P. Akkapeddi, V. Yarlagadda, J. Hoque,
D. S. S. M. Uppu, M. M. Konai, J. Haldar, J. Med. Chem. 2014, 57, 1428–
1436; b) D. Liu, W. F. DeGrado, J. Am. Chem. Soc. 2001, 123, 7553–7559.
[15] a) M. Rueping, Y. Mahajan, M. Sauer, D. Seebach, ChemBioChem 2002, 3,
257–259; b) T. B. Potocky, J. Silvius, A. K. Menon, S. H. Gellman, Chem-
BioChem 2007, 8, 917–926.
[16] a) Y. Imamura, N. Watanabe, N. Umezawa, T. Iwatsubo, N. Kato, T.
Tomita, T. Higuchi, J. Am. Chem. Soc. 2009, 131, 7353–7359; b) L. Flçp,
I. M. Mandity, G. Juhasz, V. Szegedi, A. Hetenyi, E. Weber, Z. Bozso, D.
Simon, R. Benko, Z. Kiraly, T. A. Martinek, Plos One 2012, 7, e39485.
[17] a) V. Azzarito, K. Long, N. S. Murphy, A. J. Wilson, Nat. Chem. 2013, 5,
161–173; b) V. Azzarito, J. A. Miles, J. Fisher, T. A. Edwards, S. L. Warriner,
A. J. Wilson, Chem. Sci. 2015, 6, 2434–2443; c) L. M. Johnson, W. S.
Horne, S. H. Gellman, J. Am. Chem. Soc. 2011, 133, 10038–10041; d) E. F.
Lee, J. D. Sadowsky, B. J. Smith, P. E. Czabotar, K. J. Peterson-Kaufman,
P. M. Colman, S. H. Gellman, W. D. Fairlie, Angew. Chem. Int. Ed. 2009, 48,
4318–4322; Angew. Chem. 2009, 121, 4382–4386.
[18] R. P. Cheng, S. H. Gellman, W. F. DeGrado, Chem. Rev. 2001, 101, 3219–
3232.
[19] T. A. Martinek, A. Hetenyi, L. Fulop, I. M. Mandity, G. K. Toth, I. Dekany, F.
Fulop, Angew. Chem. Int. Ed. 2006, 45, 2396–2400; Angew. Chem. 2006,
118, 2456–2460.
[20] A. Hetnyi, I. M. Mandity, T. A. Martinek, G. K. Toth, F. Fulop, J. Am.
Chem. Soc. 2005, 127, 547–553.
[21] a) F. Rﬄa, S. Boussert, T. Parella, I. Diez-Perez, V. Branchadell, E. Giralt,
R. M. Ortuno, Org. Lett. 2007, 9, 3643–3645; b) E. TorRes, J. Puigmarti-
Luis, A. P. del Pino, R. M. Ortuno, D. B. Amabilino, Org. Biomol. Chem.
2010, 8, 1661–1665; c) E. TorRes, E. Gorrea, K. K. Burusco, E. Da Silva, P.
Nolis, F. Rua, S. Boussert, I. Diez-Perez, S. Dannenberg, S. Izquierdo, E.
Giralt, C. Jaime, V. Branchadell, R. M. Ortuno, Org. Biomol. Chem. 2010,
8, 564–575.
[22] I. M. Mndity, B. Olasz, S. B. tvçs, F. Flçp, ChemSusChem 2014, 7,
3172–3176.
[23] a) N. C. Handy, A. J. Cohen, Mol. Phys. 2001, 99, 403–412; b) P. V. J. G.
Snijders, E. J. Baerends, At. Nucl. Data Tab. 1981, 26, 483–509; c) B. G.
Johnson, P. M. W. Gill, J. A. Pople, J. Chem. Phys. 1993, 98, 5612–5626;
d) C. Lee, W. Yang, R. G. Parr, Phys. Rev. B 1988, 37, 785–789.
[24] a) V. A. Guner, K. S. Khuong, K. N. Houk, A. Chuma, P. Pulay, J. Phys.
Chem. A 2004, 108, 2959–2965; b) A. P. Bento, M. Sola, F. M. Bickel-
haupt, J. Chem. Theory Comput. 2008, 4, 929–940.
[25] A. Klamt, G. Schuurmann, J. Chem. Soc. Perkin Trans. 2 1993, 799–805.
[26] T. A. Halgren, J. Comput. Chem. 1999, 20, 720–729.
Received: April 19, 2017
Version of record online && &&, 2017
ChemistryOpen 2017, 00, 0 – 0 www.chemistryopen.org  2017 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim5 &
These are not the final page numbers! 
COMMUNICATIONS
I. M. Mndity, I. Nekkaa, G. Paragi,
F. Flçp*
&& –&&
Homochirality of b-Peptides: A
Significant Biomimetic Property of
Unnatural Systems
Homochirality of artificial systems: A
characteristic property of biotic systems
is found to be a profound asset of un-
natural b-peptides. Diastereodiscrimina-
tive chain elongation of b-peptides with
various secondary structures and side
chains reveals a strong tendency toward
the construction of homochiral oligo-
mers. Water, as the cradle of life, further
enhances this property. These results
might be useful in future industrial syn-
thesis development.
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Abstract
The syntheses of various pyrimidinones as potentially bioactive products by means of the highly controlled continuous-flow retro-
Diels–Alder reaction of condensed pyrimidinone derivatives are presented. Noteworthy, the use of this approach allowed us to
rapidly screen a selection of conditions and quickly confirm the viability of preparing the desired pyrimidinones in short reaction
times. Yields typically higher than those published earlier using conventional batch or microwave processes were achieved.
Introduction
The continuous-flow (CF) technology has gained significant
importance in modern synthetic chemistry [1-3] and becomes a
core technology in the pharmaceutical, agrochemical, and fine
chemical industries [4,5]. The use of this technology opens a
new door to a quick optimization, acceleration [6], and easy
scale-up with a wide and growing range of chemical transfor-
mations in combination with an inherently safe and green nature
[7-12]. Advantageously, safety issues are complied with excel-
lent mixing and heat transfer [7-14]. These allow the access to
elevated temperatures and pressures accredited to superheating
of organic solvents in a controlled and safe fashion [6,14-17].
The accurate tuning of residence time can further broaden the
versatility of CF processes by governing the outcome of chemi-
cal reactions, determining the reaction rate and the conversion
and by influencing product selectivities [17-19]. Thus, flow
chemistry has long been selected to provide a simple means to
use more rigorous reaction conditions and revisit difficult reac-
tions that have been neglected in the past [21].
The retro-Diels–Alder (rDA) reaction has become an important
tool for synthetic chemists in their search towards the synthesis
and design of novel heterocyclic scaffolds. This pyrolytic disso-
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ciation arises when one or both fragments are notably stable
[22]. The unsaturation present in the original starting material is
produced in the DA addition, and the same atoms are involved
in both the bond formation and cleavage steps [23-25]. The rDA
process is an efficient technique for the introduction of a double
bond into a heterocyclic skeleton [26] as well as for the enantio-
divergent [27] and the enantiocontrolled [28] syntheses of
heterocyclic compounds. The rDA products can be gained, due
to a thermal [4 + 2]-cycloreversion, by distillation under
reduced pressure [29], boiling in solvent [30,31], and applying
microwave irradiation [32-35] or flash vacuum pyrolysis
[35,36]. rDA reactions under mild conditions have been widely
examined and discussed for the laboratory preparation of
heteromonocycles or condensed-ring heterocycles [37-40].
However, the CF rDA method was introduced when Meyers’
group performed the preparation of a precursor intermediate for
the construction of diverse tetracycline antibiotics [41]. Our aim
in the present study was to synthesize functionalized pyrimidi-
none systems through rDA reactions. Many of these products
are of high importance in drug design due to their diverse bio-
logical properties including antimicrobial, antiviral, antioxidant
and antitumor activities. In addition, they are present in several
natural frameworks [42-44].
We wanted to exploit the benefits of flow processing for reac-
tion optimization and synthesis and develop novel sustainable
synthetic methodologies with possible useful applications for
the pharmaceutical industry. Our results show that the de-
veloped CF technology is superior to existing conventional
batch technologies.
Results and Discussion
The starting materials, i.e., fused tricyclic or tetracyclic pyrim-
idinones 1–8 have been previously prepared by literature
methods [26,45-50]. Cyclization of the corresponding di-exo- or
di-endo-amino acids or esters with ethyl p-chlorobenzimidate
resulted in tricyclic pyrimidinones 1, 2a and 2b [26,45-49].
Methanopyrrolo-, methanopyrido- and methanoazepino[2,1-
b]quinazolinones 3–6 were prepared by ring enlargement of
di-exo-norbornene-fused azetidinones with lactim ethers [50].
For the preparation of 2-thioxopyrimidinones 7, 8a and 8b, the
most common method is the reaction of the appropriate amino
esters with phenyl isothiocyanate, followed by cyclization of
the resulting thiourea with hydrogen chloride under reflux
[45,49]. The starting materials were selected to comprise mole-
cules where good (>80%), medium (70–80%) and no conver-
sion was observed under batch rDA conditions. Batch reactions
were carried out by the following ways: heating under neat
conditions, refluxing in solvents having a high boiling point
[chlorobenzene (CB) or 1,2-dichlorobenzene (DCB)], and under
microwave (MW) conditions in DCB.
In order to provide a rapid and efficient access to the desired
pyrimidinones 9–14 (Scheme 1), we reinvestigated these rDA
reactions by using another method involving flow chemistry.
Therefore, a modular flow system was designed, equipped with
a heated 304 stainless steel coil and an adjustable back-pressure
regulator (0–300 bar) controlling the use of solvents under
superheated conditions. The coil was heated in an oven to the
desired temperature and solutions of the starting materials 1–8
were loaded into the reactor via a HPLC pump. Solvents were
selected on the basis of the solubility of the starting materials. A
schematic representation of the flow reactor setup is illustrated
in Figure 1. Products 9–14 thus prepared were identified by
means of HPLC–MS and NMR spectroscopic analysis. All
physical and spectroscopic data of pyrimidinones 9–14 were
identical with their literature data (Supporting Information
File 1).
Scheme 1: Flow synthesis for the preparation of fused pyrimidinones
9–14 by rDA reaction. Solvent and conditions (FR is the flow rate):
(i) MeCN, toluene, FR = 0.5 mL min−1, 230–250 °C; (ii) MeOH,
FR = 0.5 mL min−1, 120–150 °C; (iii) MeCN, FR = 0.5 mL min−1,
220–250 °C.
The rDA reaction is basically a thermally-driven process.
Consequently, by careful reaction parameter optimization, a
balance should be found between the desired rDA cyclorever-
sion reaction and the unwanted thermal degradation of the rDA
Beilstein J. Org. Chem. 2018, 14, 318–324.
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Figure 1: Schematic outline of the continuous-flow reactor.
Table 1: Reaction parameter optimization for the CF rDA reaction of 1.
entry temperature [°C] residence time [min] conversion [%] degradation product [%]
1 200 10 64 –
2 210 10 82 –
3 220 10 83 –
4 230 10 86 0
5 240 10 100 7
6 250 10 100 18
7 230 15 100 0
8 230 30 100 13
product. The conversion and yield of a reaction under CF condi-
tions is influenced directly by the residence time and reaction
temperature, which are crucial determining factors in flow
chemistry [18-20]. Thus, these two parameters were fine-tuned
for all of the starting materials. The residence time was set by
the use of coils with different lengths. The pressure and flow
rate of the reactions were kept at constant values of 10 bars and
0.5 mL min−1, respectively. The full reaction parameter optimi-
zation is shown only for compound 1 in Table 1.
The tricyclic di-exo-2-(4-chlorophenyl)tetrahydro-5,8-methano-
4(3H)-quinazoline (1) was dissolved in acetonitrile (MeCN) and
first the effect of the temperature was investigated. The results
show that with 10 min residence time the best conversion value
(86%) was obtained at 230 °C (Table 1, entry 4). It should be
noted that at higher temperature, a significant amount of degra-
dation product was observed and a brown oil was isolated
(Table 1, entries 5 and 6). To further improve the conversion,
the residence time was increased by utilizing longer coils
(Table 1, entries 7 and 8). It was found that complete conver-
sion can be obtained at 15 min residence time and the desired
rDA product was isolated with 92% yield (Table 1, entry 7,
Table 2, entry 1). With longer residence times, again, degrada-
tion of the product was observed. Importantly, the complete
reaction parameter optimization was carried out only in
105 min. The parameters of the optimized reaction conditions
and related results are summarized in Table 2.
In the case of di-endo-isomer 2a, higher temperature (250 °C)
but a shorter residence time was satisfactory to isolate 9 in a
yield of 95%. Furthermore, we proceeded to investigate the
elimination of cyclohexadiene from compound 2b. Because of
solubility reasons, the solvent was changed to toluene, which is
known to be compatible with high-temperature conditions [51-
53]. Retrodiene product 9 was afforded with full conversion and
in an excellent yield of 93%, which is higher than the maximum
yield (85%) reached in our previous batch work [54]. Impor-
tantly, this result was achieved with a residence time of 30 min.
Subsequently, tetracyclic methanopyrrolo-, methanopyrido- and
methanoazepino[2,1-b]quinazolinones 3–6 were examined.
Because of their excellent solubility, reactions were carried out
in methanol (MeOH). Importantly, much milder reaction
conditions gave satisfactory results. With the utilization of
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Table 2: Comparison between batch reactionsa and the CF process for the synthesis of pyrimidinones 9–14.
starting material product batch reaction (lit.) CF in the present work
method: yieldc [%] solventb temp [°C] residence time [min] yieldc [%]
1 9 A: 85 [47]B: 56 [46]
MeCN
230 15 92
2a 9 B: 54 [46]C: 85 [54] 250 10 95
2b 9
A: 63 [49]
B: 58 [49]
C: 72 [49]
toluene 230 30 93
3 10
B: 70–80 [50] MeOH
130 10 95
4 11 150 10 97
5 12 120 10 95
6 13 130 10 94
7 14 B: 80 [45]C: 89 [54]
MeCN
210 15 96
8a 14 B: 80 [45] 220 10 96
8b 14 A: B: C: 0 [49](no rDA occurred) 250 30 30
d
8b 15b – EtOH/H2O = 2:1 250 30 90
Batch reactiona: Method A: reflux, CB, 12 h; Method B: performed at their melting points; Method C: MW, solvent: DCB (2a), EtOH (7),
solvent-free (8b). bSolvents were selected on the basis of solubilities. cIsolated yield. dAfter column chromatography.
120–150 °C and only 10 min residence time, full conversions
and high yields (94–97%) were obtained. Lower yields were
previously found (70–80%) using a batch process, even upon
melting compounds 3–6 for 20 min [50].
The effect of the thioxo group on the rDA reaction was investi-
gated too with compounds 7, 8a and 8b. In the case of 7, a yield
of 96% was reached at full conversion at 210 °C in 15 min resi-
dence time. In the reaction of 8a, the di-endo isomer of 7, a
slightly higher temperature was necessary, while an appropriate
residence time of only 10 min was satisfactory to have 14 with
96% isolated yield.
On the basis of these encouraging results, we decided to further
examine the scope and limitation of the rDA reaction with the
use of our CF reactor. Di-endo-3-phenyl-2-thioxohexahydro-
5,8-ethanoquinazolin-4(1H)-one (8b) was selected, since this
compound did not lose cyclohexadiene to form monocyclic 14
under batch and microwave conditions [49]. A solution of 8b in
MeCN was treated in the heated coil reactor at 250 °C, with a
residence time of 30 min. Importantly, according to the
HPLC–MS analysis, compound 8b underwent thermal decom-
position but only a moderate conversion (36%) was detected
and 14 was isolated by means of column chromatography with a
yield of 30%. This result is due to the lack of the quasi-aromat-
ic character of the leaving cyclohexadiene, and possibly also
due to the temperature limitation of our system. Surprisingly,
however, we could detect traces of di-endo-3-phenyl-4a,5,8,8a-
tetrahydro-5,8-ethanoquinazolin-4(3H)-one (15b), resulting
from desulfurisation of 8b (Scheme 2). This observation
prompted us to investigate whether desulfurisation can occur
under the flow reactor conditions. In the literature, a similar de-
sulfurisation batch reaction was performed with nickel catalysis,
in ethanol (EtOH)/water (2:1) solution [55-57]. Thus, thioxo de-
rivative 8b was dissolved in this mixture, and the CF method
was repeated. Desulfurisation of 8b, at 250 °C without adding
any catalytic metal, provided tricyclic 15b in good yield (90%).
Most probably, the reaction was catalyzed by nickel, a compo-
nent of the 304 stainless steel reactor coil [58,59]. These results
also underline the importance to select appropriate solvents and
tubing [60,61] for thermally driven reactions. In support of our
results, tricyclic 15b was also prepared alternately: the mixture
of 3-aminobicyclo[2.2.2]oct-5-ene-carboxylic acid, triethyl-
orthoformate, aniline and acetic acid was subjected to micro-
wave irradiation at 120 W at 80 °C for 20 min. After comple-
tion of the reaction, as monitored by TLC, 20% methanolic
solution in water was added to get precipitation. The solid was
filtered off and washed with water to get di-endo-3-phenyl-
4a,5,8,8a-tetrahydro-5,8-ethanoquinazolin-4(3H)-one (15b). All
spectroscopic data of the alternately synthesized compound
were the same as those obtained by the flow chemical method.
The protocol for the synthesis of 15b and the 1H and 13C NMR
spectra of 15b are shown in Supporting Information File 1 of
this study.
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Scheme 2: Synthesis of tricyclic ethanoquinazolin-4(3H)-one 15b;
(i) MeCN, FR = 0.5 mL min−1, 220–250 °C; (ii) EtOH/H2O = 2:1,
FR = 0.5 mL min−1, 250 °C; (iii) MeCN, FR = 0.5 mL min−1, 250 °C.
A further attempt was made to perform the rDA reaction with
15b at 250 °C with a residence time of 15 min in MeCN. How-
ever, the formation of 16 was not observed, that is the starting
tetrahydroquinazolinone derivative 15b did not undergo a ther-
mally driven rDA reaction (Scheme 2). Furthermore, by
applying the same conditions on 14, no desulfurisation occurred
and the formation of 16 was not detected either.
Conclusion
In the case of compounds 1–8, HPLC–MS measurements
revealed full conversions to the desired pyrimidinones 9–14,
whereas only a moderate conversion of 8b to 14 was observed.
Mainly the retrodiene decomposition of compounds 1–8
occurred, since these latter possess the quasi-aromatic character,
through the splitting-off of cyclopentadiene or cyclohexadiene.
The stereochemistry (di-endo versus di-exo condensation) of the
starting pyrimidinones 1, 2, 7 and 8 has no significant effect on
the reaction yields. By using this safe, stable and scalable flow
process, pyrimidinones 9–14 were afforded in high purity with-
out the need for further purification steps. In addition, excellent
yields and shorter reaction times are significant further advan-
tages when compared to the corresponding batch processes.
Moreover, the flow technology allowed the replacement of
high-boiling and toxic solvents, which are commonly em-
ployed in batch process, e.g., CB or DCB, by less harmful, en-
vironmentally benign solvents such as toluene, MeCN, metha-
nol, and ethanol.
In summary, we have developed a simple flow-based method
for the preparation of pyrimidinone derivatives, precursors of a
series of pharmacologically active materials, through the rDA
reaction. The design of the reactor enabled accurate control of
both residence time and reaction temperature. CF syntheses
were performed under high-temperature conditions with varied
solvents. The CF reactor set-up ensured enhanced safety and
afforded yields higher than those for the batch and microwave
processes. These could be achieved through careful reaction pa-
rameter optimization. It is particularly true for 8b, which was
unreactive under batch conditions, in contrast to a yield of 30%
in CF. We envisage that this method can be readily extended to
the preparation of other synthetically important building blocks
requiring harsh conditions in batch methods. A simple, effi-
cient and scalable production was implemented with a short
processing time, which might open up new horizons for a
potential CF industrial synthesis of heterocycles.
Supporting Information
Supporting Information File 1
Experimental procedures and analytical data.
[https://www.beilstein-journals.org/bjoc/content/
supplementary/1860-5397-14-20-S1.pdf]
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Continuous-Flow retro-Diels–Alder Reaction: A Process Window
for Designing Heterocyclic Scaffolds
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Abstract: The synthesis of racemic and enantiopure tricyclic
and tetracyclic pyrrolopyrimidinones, pyrimidoisoindoles, and
spiropyrimidinones, as valuable new chemical entities (NCE),
based on a highly controlled continuous-flow (CF) retro-Diels–
Alder protocol is presented. This approach ensures enhanced
safety, and gave the target pyrimidinone derivatives 17–25 in
yields higher than those obtained in batch and microwave
Introduction
Heterocyclic skeletal transformations are some of the most
powerful synthetic methods for the construction of complex
molecular frameworks from simple feedstocks.[1] In this context,
Diels–Alder (DA) and retro-Diels–Alder (rDA) reactions are the
prevailing approaches, since they lead to valuable N-hetero-
cycles with high biological activities, such as isoindoloquinaz-
olinones, pyrroloquinazolinones, and 2-spiroquinazolinones.
The reactivity and skeletal transformations of these compounds
under mild conditions have been widely examined and dis-
cussed by our group.[2] The DA/rDA approach makes use of
the rigidity and chirality of the DA adducts that are formed by
reactions between cyclic dienes and cyclic dienophiles.[3,4] The
rDA enantiomers are obtained when enantiomerically pure DA
products are modified diastereoselectively and then undergo
thermal [4+2] cycloreversion through distillation under reduced
pressure[5] or boiling in a solvent,[6] or through the use of micro-
wave (MW) irradiation[7] or flash vacuum pyrolysis.[8]
We recently revealed the potential of the use of continuous-
flow (CF) technology for the synthesis of various functionalized
pyrimidinone systems through rDA reactions.[9] Our interest in
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processes. These results were achieved through careful optimi-
zation of the reaction parameters. We also developed an alter-
native time-efficient route for the synthesis of intermediate
quinazolinones 2–16 involving a three-step domino ring-clo-
sure reaction followed by spirocyclization under continuous-
flow conditions, starting from -aminonorbornene carbox-
amides 1a–1d and γ-keto acids or cycloalkanones.
CF processes can be explained, at least in part, by the number
of potential advantages that CF processes have over traditional
batch chemistry. These include the ease of scale-up, high repro-
ducibility, excellent heat transfer and mixing, as well as the in-
herently greater safety resulting from the small reactor vol-
umes.[10–19] Moreover, the accurate tuning of residence times
can further broaden the versatility of CF processes.[20] Thus,
flow chemistry has for a long time been chosen as an efficient
method for the synthesis of more complex chemical structures
that are otherwise inaccessible.
Focussing on the biological potential of fused pyrimidinones,
and continuing our work on the synthesis of new N-hetero-
cycles, we intended to further capitalize on the CF rDA protocol
by synthesizing more complex pyrimidinone-fused moieties in
both racemic and enantiopure forms. Pyrrolopyrimidines have
a wide range of applications in medicinal chemistry; they show
antimicrobial,[21] antitumor,[22] antiasthmatic,[23] antihyperten-
sive,[24] and anti-inflammatory[25] activities. Pyrimidoisoindoles
show high vasorelaxtant,[26a] antiplasmodial,[26b] and antifun-
gal[27] actions. The spiroquinazolinone, spiropiperidine, and
spiroadamantane skeletons, in turn, are known to have a wide
range of pharmacological properties, including antimalarial[28]
and anti-influenza activities.[29] Moreover, they also function as
inhibitors of several key enzymes, such as nitric oxide syn-
thase[30] and nosine-5′-monophosphate dehydrogenase.[31] In
addition, they are present in several natural frameworks, e.g.,
prostanoids, alkaloids, and nucleosides.
In this paper, we describe an extension of our previously
reported CF rDA process for the synthesis of racemic and
enantiopure tricyclic and tetracyclic pyrrolopyrimidinones, pyr-
imidoisoindoles, and spiropyrimidinone derivatives. We have
also developed an alternative preparation for quinazolinone in-
termediates by: (i) a three-step domino ring-closure reaction,
and (ii) spirocyclization under CF conditions with diexo- and
diendo--aminonorbornene carboxamides and γ-keto acids or
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cycloalkanones as starting materials. The developed flow-based
method gave the desired pyrimidinones in high yields, and en-
sures enhanced safety.
Results and Discussion
Our previous investigations on the CF rDA reactions of con-
densed pyrimidinone derivatives revealed that the CF approach
is superior to existing conventional batch methods.[9] In this
work, starting materials were selected with the aim of testing
the viability of the proposed CF rDA protocol with more com-
plex fused pyrimidinone moieties, and also of investigating mo-
lecules that have never been subjected to rDA reactions under
batch conditions. We started our study with readily available
aminocarboxamides 1a–1d, which were prepared by known lit-
erature approaches. Both diendo- and diexo-3-aminobicy-
clo[2.2.l]hept-5-ene-2-carboxylic acids, as well as diexo-3-amino-
7-oxabicyclo[2.2.1]hept-5-enecarboxylic acid, were esterified
with ethanol, and the resulting ester bases were liberated from
the hydrochlorides. These aminoesters were kept for three
weeks in a large excess of methanol saturated with ammonia
to give amides 1a, 1c, and 1d.[2d,2f,2l] For the preparation of 3-
exo-amino-N-methylbicyclo[2.2.l]hept-5-ene-2-exo-carboxamide
(1b), a mixture of the appropriate ester and a methylaminesolu-
tion (25 % in methanol) was kept for 6 d at room tempera-
ture.[2e] Our synthetic efforts began with the preparation of the
required intermediates 2–16 using an optimized procedure
based on previously reported methods,[2l–2r] as illustrated in
Schemes 1 and 2.
Scheme 1. Solvent and conditions: (i) toluene, reflux, pTsA, 16 h;[2l–2n] (ii) CF: toluene, flow rate = 0.2 mL min–1, 110 °C, pTsA, 6 h.
Scheme 2. Solvent and conditions: (i) 8, 9: solventless, room temp., 2 d.[2q] 10: EtOH, reflux, 2 h.[2o] 11–13: H2O, room temp., 24 h;[2q] (ii) CF: EtOH, flow rate =
0.2 mL min–1, 100 °C, 6 h; (iii) MW: EtOH, 100 °C, 1 h; (iv) CF: EtOH, flow rate = 0.2 mL min–1, 100 °C, 6 h.
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The cyclization reactions of racemic diexo-3-aminobicyclo-
[2.2.1]hept-5-ene-2-carboxamide (1a) or diexo-3-N-methylbicy-
clo[2.2.1]hept-5-ene-2-carboxamide (1b) with γ-oxocarboxylic
acids in toluene under reflux in the presence of para-toluene-
sulfonic acid (pTsA), through three-step domino reactions, re-
sulted in single diasteroisomers of pyrrolo[1,2-a]quinazolines 2–
4 or isoindolo[2,1-a]quinazolines 5–7 (Scheme 1). Upon heating
with cyclohexanone in refluxing ethanol (EtOH), -aminonor-
bornene carboxamides 1a, 1c, and 1d were cyclized to give
methylene- and epoxy-bridged 2-spiroquinazolinones 8–10.
These compounds could alternatively be prepared under dry
(solvent-free) conditions by stirring for 2 d; spiropiperidine de-
rivatives 11–13 were formed by the condensation of carbox-
amides 1a, 1c, and 1d with 1-benzylpiperidin-4-one in water at
room temperature (Scheme 2).
For the preparation of spiro[quinazoline-2,2′-adamantane]
derivatives 14–16, we developed an alternative synthetic path-
way involving the use of MW irradiation on 1a, 1c, 1d with
adamantanone in EtOH (Scheme 2). This reaction has previously
also been carried out in a vibrational ball mill with iodine (I2)
as a catalyst.[2r] In additition, we wanted to further develop this
cyclization method by searching for a time-efficient method for
the synthesis of functionalized intermediates 2–16. To this end,
a CF-based strategy seemed highly appropriate , since this ap-
proach has emerged as an intense area of current research, be-
ing used for the synthesis of many different heterocyclic scaf-
folds.[32] -Amino amides 1a–1d were mixed with γ-keto acids
or cyclic ketones and loaded into the CF reactor constructed
previously (Figure 1), using the same operating conditions and
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solvents used before in batch syntheses. Mixtures of 1a or 1b
and γ-keto acids were dissolved in toluene, and introduced into
the flow reactor at 110 °C, with 6 h as the reaction time: Tetra-
and pentacyclic derivatives 2–7 were obtained in slightly higher
yields (79–93 %) than the previous batch method.Heating solu-
tions of 1a, 1c, or 1d with cycloalkanones in EtOH at 100 °C
gave spiroquinazolinones 8–16 with reaction times of 6 h in
similar yields (79–95 %). Note, however, that shorter reaction
times were needed for cyclization in the CF reactions (see
Table S1 in the Supporting Information).
Figure 1. Set-up of the continuous-flow reactor.
The residence time and reaction temperature are crucial de-
termining factors in flow chemistry;[20] they control the course
of a reaction by affecting both the conversion and the yield.
Thus, these two parameters were well-tuned for all starting ma-
terials. The residence time was set by the use of coils with differ-
ent lengths. The pressure and flow rate were kept at constant
values of 10 bar and 0.2 mL min–1, respectively. The reaction
process was monitored by means of HPLC–MS and 1H NMR
spectroscopic analysis.
Our next step was to investigate the transformation of quin-
azolinone derivatives 2–16 into retrodiene products 17–25
through a thermal [4+2] cycloreversion involving the elimina-
tion of cyclopentadiene or furan from DA adducts (Scheme 3).
We began by investigating the CF rDA reactions of tetra- and
pentacyclic derivatives 2–7, since these compounds include
Scheme 3. (i) CF: MeCN, toluene, flow rate = 0.2 mL min–1, 150–250 °C; (ii) heating at melting points; (iii) MW: 1,2-DCB (1,2-dichlorobenzene), 150–240 °C, 1 h.
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more complex fused pyrimidinone moieties, which might be a
challenge for our proposed CF rDA protocol.
We screened different solvents, and found that polar aprotic
solvents such as acetonitrile (MeCN) or methanol (MeOH) were
preferred over nonpolar solvents (dichloromethane, toluene),
especially when high concentrations were used. We thus opted
for MeCN as a suitable and benign solvent, and used it subse-
quently to study the effect of different temperatures. We
quickly established that temperatures of 220–250 °C gave full
conversions with a residence time of 15 min, without the un-
wanted thermal degradation of the rDA products; lower tem-
peratures slowed down the reactions significantly. Having es-
tablished these reaction conditions, tetracyclic pyrrolo[1,2-a]-
quinazolinones 2–4 and pentacyclic isoindolo[1,2-a]quinazolin-
ones 5–7 were dissolved in MeCN, and after 5 min of stirring
at ambient temperature, the homogeneous mixtures were in-
troduced into the reactor by an HPLC pump (Figure 1). Heating
the mixtures at 220 or 250 °C led to the expected pyrrolopyrim-
idinones 17–19 and pyrimidoisoindoles 20–22, with residence
times of 15 min (Table 1, entries 1–8) in isolated yields over
90 % after purification by column chromatography. These re-
sults match the parent batch experiments in terms of isolated
yields.[2l,2m]
To establish the range of applicability of our CF rDA process,
the syntheses of enantiomerically pure pyrrolo[1,2-a]pyrim-
idine 19 and pyrimido[2,1-a]isoindole 20 through rDA reaction
under CF conditions were undertaken (Scheme 4). The source
of chirality, (1R,2R,3S,4S)-3-amino-N-methylbicyclo[2.2.1]hept-5-
ene-2-carboxamide [(–)-1b] was prepared by known literature
protocols.[2e] In a stereocontrolled ring-closing reaction, (–)-1b
was treated with 3-oxo-3-(p-tolyl)propanoic acid to give (+)-4
as a single diastereoisomer in good yield. The ready loss of
cyclopentadiene through the CF rDA protocol at 220 °C resulted
in (S)-1-methyl-8a-(p-tolyl)-1,7,8,8a-tetrahydropyrrolo[1,2-a]pyr-
imidine-2,6-dione enantiomer (+)-19 in high yield (Table 1, en-
try 4) with an ee value of 97 %. When carboxamide (–)-1b was
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Table 1. CF process for the synthesis of pyrimidinones 17–25 under the opti-
mized reaction conditions.
Entry Starting Product CF Optimized reaction conditions
material Solvent[a] T Residence Yield[b]
[°C] time [min] [%]
1 2 17 MeCN 250 15 98
2 3 18 220 15 97
3 4 19 220 15 95
4 (+)-4 (+)-19 220 15 97
5 5 20 220 15 98
6 (+)-5 (–)-20 250 15 93
7 6 21 220 15 96
8 7 22 250 15 97
9 8 240 60 73
10 9 23 240 60 75
11 10 150 60 95
12 11 toluene/ 240 60 53
13 12 24 MeOH, 240 60 70
14 13 4:1 150 60 92
15 14 240 60 51
16 15 25 240 60 57
17 16 150 60 86
[a] Solvents were selected on the basis of solubilities. [b] Isolated yield.
treated with 2-formylbenzoic acid, pentacyclic isoindolo-
[1,2-a]quinazolinone (+)-5 was formed. CF-induced thermolysis
of (+)-5 at 250 °C gave the expected (S)-1-methyl-1,10b-di-
hydropyrimido[2,1-a]isoindole-2,6-dione [(–)-20] within a resi-
dence time of 15 min, with full conversion, in high yield, and
with an ee value of 98 % (Table 1, entry 6).
Our next CF rDA investigation was carried out with spiro-
quinazolinones 8–16, which have not been subjected to rDA
reactions previously through conventional batch approaches.
Spiroquinazolinone derivatives 8–16 were first subjected to CF
using the previously optimized parameters. They were dissolved
in MeCN and loaded into the CF reactor (Figure 1) at different
temperatures based on their melting points. An initial assess-
ment of the results revealed that compounds 8–16 underwent
thermal decomposition, but only moderate conversions were
observed with significant amounts of rDA degradation prod-
ucts. Following these disappointing results, we decided to opti-
Scheme 4. Solvent and conditions: (i) toluene, reflux, pTsA, 16 h; (ii) CF: toluene, pTsA, flow rate = 0.2 mL min–1; (iii) CF: MeCN, toluene, flow rate = 0.2 mL min–
1, 220 °C.
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mize our operating parameters further. We screened different
solvents, and found that a mixture of toluene and MeOH
(4:1 v/v) worked best to give new 2-spiropyrimidin-4-ones 23–
25. It is important to note that toluene is known to be an effec-
tive solvent under superheated CF rDA conditions.[9,33] This ef-
fect is even more pronounced when MeOH is used as a cosolv-
ent. The transformation of diexo-methylene-bridged 2-spiro-
quinazolinone 8 is illustrative. The substrate was dissolved in
toluene/MeOH (4:1), and the solution was introduced into the
heated 304 stainless steel coil reactor at 240 °C with a residence
time of 60 min (Table 1, entry 9). The residence time was in-
creased by using a longer coil in order to further improve the
conversion. Under these conditions, 1,5-diazaspiro[5.5]undec-3-
en-2-one (23) was isolated in a moderate yield of 73 %.
We also wanted to investigate the CF rDA reaction of diendo
isomer 9 in the hope that we could increase the yield of 23.
Since diendo stereoisomers are thermally unstable compared to
their diexo analogues, they undergo rDA reactions more easily.
Thus, 9 was subjected to the same conditions as described
above (Table 1, entry 10). With a residence time of 60 min, rDA
product 23 was obtained in almost the same yield (75 %) as
with diexo isomer 8. This result shows that a change in stereo-
chemistry does not have any significant effect on the reaction
yield. Subsequently, we turned to epoxy-bridged 2-spiroquinaz-
olinone 10 with the expectation that it would be much easier
to remove furan as the diene than cyclopentadiene, and that
this would be achieved at lower temperatures. This may im-
prove the yield by increasing the conversion and minimizing
the amount of degradation products because of the lower tem-
peratures used. Therefore, we used a temperature of 150 °C.
Complete conversion was obtained with a residence time of
60 min, and the desired spiro compound 23 was isolated in a
yield of 95 % (Table 1, entry 11). Encouraged by these promis-
ing results, a series of experiments was undertaken to gain a
better understanding of the effect of the thermally-driven CF
rDA on the transformation of other spiroquinazolinone scaf-
folds. Accordingly, we treated compounds 11–16 under the CF
reaction conditions described above. Benzylpiperidine deriva-
tive 24 and adamantane 25 were obtained in good yields of 92
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and 86 %, respectively (Table 1, entries 14 and 17). Importantly,
the yields obtained from the oxa-bridged spiro compunds were
always higher than those for the methylene-bridged analogues.
Based on our previous findings, we wanted to explore
whether spiro compounds 8–16 undergo thermal decomposi-
tion under conventional batch conditions. For this purpose, we
planned to test two different batch methods (Scheme 3). The
first method involved simple heating of compounds 8–16 at
their melting points; in the second method, the rDA reactions
were carried out under MW conditions. Thus, in solvent-free
experiments, compounds 8–16 were heated at around 10 °C
above their melting points. Although HPLC–MS analysis showed
full degradation of starting materials 8–16, rDA products 23–
25 were not detected in any case. In contrast, when MW irradia-
tion was used with spiroquinazolinone derivatives 8–16, we ob-
served slightly higher than medium or no conversion to the
retrodiene products 23–25.
The best MW-promoted cycloreversion for the synthesis of
compounds 23–25 was achieved when epoxy-spiroquinazolin-
ones 10, 13, and 16 were irradiated in 1,2-dichlorobenzene at
180 °C for 30 min. These conditions gave isolated yields of 78,
89, and 78 %, respectively (Figure 2). These yields are lower than
those obtained in the CF rDA process (Table 1, entries 11, 14,
and 17). A throughput comparison for spiropyrimidinones 23–
25 prepared by the batch and CF processes is shown in Fig-
ure 2. These data clearly demonstrate the superiority of CF tech-
nology compared to conventional batch methods.
Figure 2. Comparison in terms of isolated yields between the CF rDA and
MW processes for the synthesis of functionalized spiropyrimidinones 23–25.
MW-induced rDA (orange); CF rDA (blue).
Conclusions
A detailed investigation of the CF rDA reaction, a new and effi-
cient approach to the synthesis of pyrrolopyrimidinone (17–
19), pyrimidoisoindole (20–22), and spiropyrimidinone (23–25)
derivatives has been carried out. The preparation of intermedi-
ates 2–16 through domino ring closure or spirocyclization un-
der CF conditions was achieved in high yields; this protocol
represents an alternative time-efficient route. We proved that
the CF rDA process is able to yield more complex structures
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that are otherwise inaccessible. In the case of pyrrolo[1,2-a]-
quinazoline and isoindolo[2,1-a]quinazoline derivatives 2–7,
HPLC–MS measurements revealed full conversions to the de-
sired pyrrolopyrimidinones and isoindolopyrimidinones 17–22.
In contrast, only moderate conversions to new spiropyrimodi-
nones 23–25 were observed for the methylene-bridged spiro-
quinazolinones 8, 9, 11, 14, and 15. It is interesting that epoxy-
bridged spiroquinazolinones 10, 13, and 16, in which an oxy-
gen atom has been introduced at the 7-position of the
-aminonorbornene carboxamide skeleton, gave retrodiene
products 23–25 in almost quantitative yields. Importantly, the
stereochemistry (diendo vs. diexo condensation) of the starting
quinazolinones 8–16 was found to have no significant effect on
reaction yields. The CF reactor set-up ensured enhanced safety,
and gave yields higher than those obtained in batch and micro-
wave processes. This is particularly true for compounds 11, 14,
and 15, which were unreactive (0 % yield) under microwave
conditions; yields of 53, 51, and 57 %, respectively, were ob-
served under CF conditions. We envisage that this approach
could be readily extended to the preparation of other syntheti-
cally important building blocks that require harsh conditions in
batch methods.
Experimental Section
General Remarks: 1H NMR spectra were recorded at 400.13 MHz
or 500.20 MHz, and 13C NMR spectra were recorded at 100.62 MHz
or 125.77 MHz in CHCl3 or [D6]DMSO at ambient temperature, with
a Bruker AM 400 or a Bruker AscendTM 500 spectrometer. Chemical
shifts (δ) are given in parts per million (ppm) relative to tetramethyl-
silane (δ = 0 ppm), which was used as an internal standard. 1H NMR
spectra were calibrated using the residual solvent signals of CDCl3
(δ = 7.26 ppm) or [D6]DMSO (δ = 2.50 ppm). 13C NMR spectra were
calibrated using the signal of CDCl3 (δ = 77.16 ppm) or [D6]DMSO
(δ = 39.52 ppm). Signal multiplicities are reported as follows: s =
singlet, d = doublet, t = triplet, q = quartet, m = multiplet; ArH =
aromatic. Data for 13C NMR are reported in terms of chemical shift
(δ [ppm]) and multiplicity (C, CH, CH2, CH3 or NH). Coupling con-
stants (J) are reported to the nearest 0.1 Hz. Copies of the 1H and
13C spectra can be found in the Supporting Information. HPLC–MS
measurements were carried out with a Phenomenex 5 μm C18(2)
100 Å column (250 × 4.60 mm). The solvent systems used consisted
of AcOH (0.1 %) in water (A) and AcOH (0.1 %) in MeCN (B); gradient:
5–100 % B over 35 min, at a flow rate of 1 mL min–1. Chromato-
grams and spectra were recorded in positive-ion mode with electro-
spray ionization with a Thermo LCQ Fleet mass spectrometer. FTIR
spectra were obtained using KBr pastilles with an AVATAR 330 FTIR
Thermo Nicolet spectrometer. Flow reactions were carried out with
a modular flow system equipped with heated 304 stainless steel
tubing coils [Supelco premium grade 304 empty stainless steel tub-
ing; dimensions: length (L) × outer diameter (OD) × inner diameter
(ID) = 100 ft × 1/16 in × 0.03 in] and an adjustable back-pressure
regulator (ThalesNano, BPR, 0–300 bar). The tube reactor was
heated in a Heraeus oven to the desired temperatures. The pressure
was set at 10 bar, and the flow rate was kept at a constant value of
0.2 mL min–1. Microwave-promoted reactions were carried out in
sealed reaction vials (10 mL) in a microwave (CEM, Discover) cavity.
Melting points were measured with a Hinotex X4 micro melting-
point apparatus with a heating rate of 4 °C/min. Optical rotations
for the rDA products were recorded with a Perkin-Elmer 341
polarimeter. The corresponding ee values were 97 % for (+)-19 and
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98 % for (–)-20. Analysis of these compounds was carried out using
an HPLC instrument equipped with a Phenomenex IA column. For
(+)-19: n-hexane/iPrOH, 70:30, 0.1 % Et2NH, flow rate 0.5 mL min–1,
detection at 254 nm, tR = 63.50 min (antipode: 56.95 min); for (–)-
20: n-hexane/iPrOH , 70:30, flow rate 1.0 mL min–1, detection at
254 nm, tR = 28.50 min (antipode: 22.51 min). All physical and spec-
troscopic data of fused pyrimidinones 2–22 were identical with the
corresponding literature data.[2l,2m,2o,2q,2r]
General Procedures for Flow Reactions
Synthesis of Ring-Closure Products 2–16
Synthesis of Pyrrolo[1,2-a]quinazolines 2, 3, 4 and Isoindolo-
[1,2-a]quinazolines 5, 6, and 7: A mixture of diexo-3-aminobicy-
clo[2.2.1]hept-5-ene-2-carboxamide (1a) or diexo-3-amino-N-meth-
ylbicyclo[2.2.1]hept-5-ene-2-carboxamide (1b) (1 mmol) and either
levulinic acid, 3-oxo-3-(p-tolyl)propanoic acid, 2-formylbenzoic acid,
2-acetylbenzoic acid, or 2-(4-methylbenzoyl)benzoic acid (1.2 mmol)
along with a catalytic amount of pTsA was dissolved in toluene
(50 mL). The system temperature was set to 110 °C, the pressure to
10 bar, and the flow rate to 0.2 mL min–1. When the pressure and
the temperature of the flow system were stable, the solution loaded
into the reactor was passed through the heated reactor coil with a
reaction time of 6 h. The flow output was collected. The solvent
was removed by evaporation, and the solid residue was dissolved
in EtOAc/MeOH, 9:1 (v/v). The solution was transferred to a neutral
SiO2 column, which was eluted with the same solvent mixture. The
analytical and spectroscopic data of 2–7 were identical to those
found in the literature.[2l,2m]
(3aR*,5aR*,6R*,9S*,9aS*)-3a-Methyl-2,3,3a,4,5a,6,9,9a-octa-
hydro-6,9-methanopyrrolo[1,2-a]quinazoline-1,5-dione (2): Col-
ourless crystals (93 %). M.p. 239–242 °C. HPLC–MS (ESI): tR =
12.00 min, m/z = 233 [M + H]+, 167 [MrDA + H]+. The analytical
and spectroscopic data of 2 were identical to those reported in the
literature.[2l]
(3aR*,5aR*,6R*,9S*,9aS*)-6,9-Methano-3a,4-dimethyl-
2,3,3a,4,5a,6,9,9aoctahydropyrrolo[1,2-a]quinazoline-1,5-dione
(3): Colourless crystals (85 %). M.p. 207–209 °C. HPLC–MS (ESI): tR =
13.89 min, m/z = 247 [M + H]+, 181 [MrDA + H]+. The analytical
and spectroscopic data of 3 were identical to those reported in the
literature.[2m]
(3aS*,5aR*,6R*,9S*,9aS*)-6,9-Methano-4-Methyl-3a-(p-tolyl)-
2,3,3a,4,5a,6,9,9a-octahydropyrrolo[1,2-a]quinazoline-1,5-di-
one (4): Colourless crystals (79 %). M.p. 214–216 °C. HPLC–MS (ESI):
tR = 24.49 min, m/z = 323 [M + H]+, 229 [MrDA + H]+. The analytical
and spectroscopic data of 4 were identical to those reported in the
literature.[2m]
( 1S * , 4R * , 4aR * , 6aS * , 12aS * ) -1 ,4 -Methano -6 -methy l -
1,4,4a,6,6a,12a-hexahydroisoindolo[2,1-a]quinazoline-5,11-di-
one (5): Colourless crystals (90 %). M.p. 197–198 °C. HPLC–MS (ESI):
tR = 18.70 min, m/z = 281 [M + H]+, 215 [MrDA + H]+. The analytical
and spectroscopic data of 5 were identical to those reported in the
literature.[2m]
(1S*,4R*,4aR*,6aR*,12aS*)-1,4-Methano-6,6a-dimethyl-
1,4,4a,6,6a,12a-hexahydroisoindolo[2,1-a]quinazoline-5,11-di-
one (6): Colourless crystals (83 %). M.p. 196–197 °C. HPLC–MS (ESI):
tR = 21.84 min, m/z = 295 [M + H]+, 229 [MrDA + H]+. The analytical
and spectroscopic data of 6 were identical to those reported in the
literature.[2m]
(1S*,4R*,4aR*,6aR*,12aS*)-1,4-Methano-6-methyl-6a-(p-tolyl)-
1,4,4a,6,6a,12a-hexahydroisoindolo[2,1-a]quinazoline-5,11-di-
one (7): Colourless crystals (85 %). M.p. 230–232 °C. HPLC–MS (ESI):
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tR = 31.72 min, m/z = 371 [M + H]+, 305 [MrDA + H]+. The analytical
and spectroscopic data of 7 were identical to those reported in the
literature.[2m]
Synthesis of Enantiomeric Pyrrolo[1,2-a]quinazoline (+)-4 and
Isoindolo[1,2-a]quinazoline (+)-5: A mixture of (–)-(1R,2R,3S,4S)-3-
amino-N-methylbicyclo[2.2.1]hept-5-ene-2-carboxamide [(–)-1b,
1 mmol] and either 3-oxo-3-(p-tolyl)propanoic acid or 2-formylben-
zoic acid (1.2 mmol) along with pTsA (5 mg) in toluene (50 mL) was
introduced into the flow reactor at a temperature of 110 °C, using
the same flow rate (0.2 mL min–1). The product mixture (brownish-
yellow colour) leaving the flow system was evaporated. The residue
was dissolved in EtOAc/MeOH (9:1) eluent, and this material was
directly transferred onto a short SiO2 column. The 1H and 13C NMR
spectroscopic data for the optically active compounds were consist-
ent with those reported for the racemates.
(+)-(3aR,5aR,6R,9S,9aS)-6,9-Methano-4-methyl-3a-(p-tolyl)-
2,3,3a,4,5a,6,9,9a-octahydropyrrolo[1,2-a]quinazoline-1,5-di-
one [(+)-4]: Colourless crystals (82 %). M.p. 206–208 °C. [α]D25 =
+10.8 (c = 0.33, MeOH).
( + ) - ( 1S , 4R , 4 aR , 6 aS , 1 2aS ) - 1 , 4 –Me thano - 6 -me thy l -
1,4,4a,6,6a,12a-hexahydroisoindolo[2,1-a]quinazoline-5,11-di-
one [(+)-5]: Colourless crystals (83 %). M.p. 250–252 °C. [α]D25 = +62
(c = 0.48, MeOH).
Preparation of Spiroquinazolinones 8–16: A solution of amino-
carboxamide 1a, 1c, or 1d (1 mmol) and either cyclohexanone, 1-
benzylpiperidine, or adamantanone (1.2 mmol) in EtOH (50 mL),
was fed into the reactor, and passed through the heated reactor
coil at 100 °C with a reaction time of 6 h. The flow output was
collected. The solvent was removed by evaporation, and the re-
maining residue was dissolved in Et2O (5 mL). The resulting crystals
were collected by filtration and washed with Et2O. The analytical
and spectroscopic data on 8–16 were identical to those reported
in the literature.[2o–2r]
(4aR*,5R*,8S*,8aS*)-4a,5,8,8a-Tetrahydro-1H-spiro[5,8-meth-
anoquinazoline-2,1′-cyclohexan]-4(3H)-one (8): Colourless pow-
der (95 %). M.p. 232–235 °C. HPLC–MS (ESI): tR = 6.52 min, m/z =
233 [M + H]+, 167 [MrDA + H]+. The analytical and spectroscopic
data of 8 were identical to those reported in the literature.[2q]
(4aS*,5R*,8S*,8aR*)-4a,5,8,8a-Tetrahydro-1H-spiro[5,8-meth-
anoquinazoline-2,1′-cyclohexan]-4(3H)-one (9): Colourless pow-
der (98 %). M.p. 243–244 °C. HPLC–MS (ESI): tR = 6.23 min, m/z =
233 [M + H]+, 167 [MrDA + H]+. The analytical and spectroscopic
data of 9 were identical to those reported in the literature.[2o]
(4aS*,5R*,8S*,8aR*)-4a,5,8,8a-Tetrahydro-1H-spiro[5,8-epoxy-
quinazoline-2,1′-cyclohexan]-4(3H)-one (10): Colourless crystals
(89 %). M.p. 158–160 °C. HPLC–MS (ESI): tR = 6.49 min, m/z = 235
[M + H]+, 167 [MrDA + H]+. The analytical and spectroscopic data of
10 were identical to those reported in the literature.[2o]
(4aR*,5R*,8S*,8aS*)-1 ′-Benzyl-4a,5,8,8a-tetrahydro-1H-
spiro[5,8-methanoquinazoline-2,4′-piperidin]-4(3H)-one (11):
Colourless powder (95 %). M.p. 217–220 °C. HPLC–MS (ESI): tR =
9.7 min, m/z = 324 [M + H]+, 258 [MrDA + H]+. The analytical and
spectroscopic data of 11 were identical to those reported in the
literature.[2q]
(4aS*,5R*,8S*,8aR*)-1 ′-Benzyl-4a,5,8,8a-tetrahydro-1H-
spiro[5,8-methanoquinazoline-2,4′-piperidin]-4(3H)-one (12):
White powder (92 %). M.p. 248–250 °C. 1H NMR (500 MHz,
[D6]DMSO): δ = 0.63 (d, J = 10.96 Hz, 1 H, 9-H), 1.35–1.41 (m, 3 H,
9-H, CH2), 1.47–1.69 (m, 2 H, CH2), 1.87 (m, J = 12.8 Hz, 1 H, 1-NH),
2.24–2.4 (m, 4 H, CH2), 2.96 (s, 1 H, 8-H), 3.14 (s, 1 H, 5-H), 3.44 (s, 2
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H, NCH2Ar), 3.72 (t, J = 8.6 Hz, 1 H, 8a-H), 6.14–6.21 (m, 2 H, 6-H, 7-
H), 7.20–7.32 (m, 5 H, ArH), 7.79 (s, 1 H, 3-NH) ppm. 13C NMR
(125.77 MHz, CDCl3): δ = 36.53, 37.50, 42.80, 45.86, 46.37, 47.02,
49.03, 49.72, 54.39, 62.40, 67.87, 127.27, 127.29, 128.59. 128.61,
129.21, 129.24, 133.87, 133.89, 139.34, 139.36, 171.47. HPLC–MS
(ESI): tR = 9.42 min, m/z = 324 [M + H]+, 258 [MrDA + H]+.
(4aS*,5R*,8S*,8aR*)-1 ′-Benzyl-4a,5,8,8a-tetrahydro-1H-
spiro[5,8-epoxyquinazoline-2,4′-piperidin]-4(3H)-one (13): Col-
ourless powder (90 %). M.p. 196–197 °C. 1H NMR (500 MHz, CDCl3):
δ = 1.6–1.9 (m, 4 H, CH2), 1.85–1.95 (m, 1 H, 1-NH), 2.14 (d, J =
6.5 Hz, 1 H, 4a-H), 2.48–2.64 (m, 4 H, CH2), 3.36 (s, 1 H, 8a-H), 3.54
(s, 2 H, NCH2Ar), 4.84 (s, 1 H, 8-H), 5.42 (s, 1 H, 5-H), 6.31 (s, 1 H, 3-
NH), 6.36 (dd, J = 5.8, J = 1.5 Hz, 1 H, 7-H), 6.57 (dd, J = 5.86, J =
1.45 Hz, 1 H, 6-H) , 7 .27–7.33 (m, 1 H, ArH) ppm. 13C NMR
(125.77 MHz, CDCl3): δ = 35.8, 42.8, 48.8, 49.4, 52.4, 62.7, 67.9, 81.8,
83.2, 128.3, 129.0, 133.5, 138.5, 170.3. HPLC–MS (ESI): tR = 6.86 min,
m/z = 326 [M + H]+, 258 [MrDA + H]+.
(4aR*,5R*,8S*,8aS*)-4a,5,8,8a-Tetrahydro-1H-spiro[5,8-meth-
anoquinazoline-2,2′-adamantan]-4(3H)-one (14): Colourless
powder (82 %). M.p. 218–220 °C. HPLC–MS (ESI): tR = 12.45 min,
m/z = 285 [M + H]+, 219 [MrDA + H]+. The analytical and spectro-
scopic data of 14 were identical to those reported in the litera-
ture.[2r]
(4aS*,5R*,8S*,8aR*)-4a,5,8,8a-Tetrahydro-1H-spiro[5,8-meth-
anoquinazoline-2,2′-adamantan]-4(3H)-one (15): Colourless crys-
tals (83 %). M.p. 207–210 °C. HPLC–MS (ESI): tR = 11.49 min, m/z =
285 [M + H]+, 219 [MrDA + H]+. The analytical and spectroscopic
data of 15 were identical to those reported in the literature.[2r]
(4aS*,5R*,8S*,8aR*)-4a,5,8,8a-Tetrahydro-1H-spiro[5,8-epoxy-
quinazoline-2,2′-adamantan]-4(3H)-one (16): Colourless crystals
(79 %). M.p. 175–178 °C. HPLC–MS (ESI): tR = 14.19 min, m/z = 287
[M + H]+, 219 [MrDA + H]+. The analytical and spectroscopic data of
16 were identical to those reported in the literature.[2r]
Synthesis of Retrodiene Products 17–22
Preparation of Racemic Pyrrolo[1,2-a]pyrimidines 17–19 and
Pyrimido[1,2-a]isoindoles 20–22: Compounds 2–7 (100 mg) were
each introduced into the flow reactor in a solution of MeCN (25 mL).
The solution was inserted into the reactor, and passed through the
heated reactor coil at 220 °C or 250 °C (for 2 and 7), with a residence
time of 15 min, and the flow output was collected. The solvent was
removed by evaporation, and the residue was dissolved in Et2O
(5 mL). The resulting crystals were collected by filtration and
washed with Et2O.
8a-Methyl-1,7,8,8a-tetrahydropyrrolo[1,2-a]pyrimidine-2,6-di-
one (17): Colourless crystals (98 %). M.p. 165–166 °C. 1H NMR
(500 MHz, [D6]DMSO): δ = 1.41 (s, 3 H, CH3), 2.03–2.18 (m, 2 H, CH2),
2.41–2.47 (m, 1 H, CH2), 2.67–2.58 (m, 1 H, CH2), 5.24 (dd, J = 7.70,
J = 1.90 Hz, 1-H, 3-H), 7.30–7.32 (d, J = 7.72 Hz, 1 H, 4-H), 8.22 (s, 1
H, NH) ppm. 13C NMR (125.77 MHz, [D6]DMSO): δ = 24.5, 29.5, 33.9,
73.6, 105.5, 131.2, 163.58, 170.8 ppm. HPLC–MS (ESI): tR = 7.11 min,
m/z = 167 [M + H]+.
1,8a-Dimethyl-8,8a-dihydropyrrolo[1,2-a]pyrimidine -
2,6(1H,7H)-dione (18): Colourless crystals (98 %). M.p. 130–131 °C.
1H NMR (500 MHz, CDCl3): δ = 1.46 (s, 3 H, 8a-CH3), 2.25–2.36 (m, 2
H, CH2), 2.52–2.66 (m, 2 H, CH2), 2.9 (s, 3 H, 1-CH3), 5.47 (d, J =
7.6 Hz, 1 H, 3-H), 7.27 (d, J = 6.49 Hz, 1 H, 4-H) ppm. 13C NMR
(125.77 MHz, CDCl3): δ = 19.4, 26.9, 29.6, 32.8, 106.0 129.6, 163.3,
169.7 ppm. HPLC–MS (ESI): tR = 9.12 min, m/z = 181 [M + H]+.
1-Methyl-8a-(p-tolyl)-8,8a-dihydropyrrolo[1,2-a]pyrimidine-
2,6(1H,7H)-dione (19): Colourless crystals (99 %). M.p. 121–123 °C.
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1H NMR (500 MHz, CDCl3): δ = 2.34 (s, 3 H, ArCH3), 2.61–2.74 (m, 4
H, CH2), 3.16 (s, 3 H, 1-CH3), 5.48 (d, J = 7.66 Hz, 1 H, 3-H), 7.08 (d,
J = 8.35 Hz, 2 H, , Ar), 7.17 (d, J = 8.04 Hz, 2 H, Ar), 7.32 (d, J =
7.64 Hz, 1 H, , 4-H) ppm. 13C NMR (125.77 MHz, CDCl3): δ = 20.9,
29.6, 30.0, 33.7, 80.3, 107.6, 124.7, 129.6, 130.3, 137.1, 139.2, 163.6,
170.8 ppm. HPLC–MS (ESI): tR = 19.56 min, m/z = 257 [M + H]+.
1-Methyl-1,10b-dihydropyrimido[2,1-a]isoindole-2,6-dione
(20): Colourless crystals (98 %). M.p. 165–167 °C. 1H NMR (500 MHz,
CDCl3): δ = 3.20 (s, 3 H, CH3), 5.64 (d, J = 7.51 Hz, 1 H, 4-H), 5.99 (s,
1 H, 10b-H), 7.63–7.76 (m, 4 H, Ar), 7.98 (d, J = 7.51 Hz, 1 H, 3-H)
ppm. 13C NMR (125.77 MHz, CDCl3): δ = 29.2, 70.9, 107.2, 125.3,
125.4, 130.6, 131.9, 132.7, 133.1, 138.7, 164.2, 165.4 ppm. HPLC–MS
(ESI): tR = 15.44 min, m/z = 215 [M + H]+.
1,10b-Dimethyl-1,10b-dihydropyrimido[2,1-a]isoindole-2,6-di-
one (21): Colourless crystals (98 %). M.p. 236–238 °C. 1H NMR
(500 MHz, CDCl3): δ = 1.72 (s, 3 H, 10b-CH3), 3.13 (s, 3 H, 1-CH3),
5.72 (d, J = 7.48 Hz, 1 H, 4-H), 7.54 (d, J = 7.49 Hz, 1 H, Ar), 7.63–
7.76 (m, 3 H, Ar), 7.97 (d, J = 8.04 Hz, 1 H, 3-H) ppm. 13C NMR
(125.77 MHz, CDCl3): δ = 22.4, 28.4, 107.8, 124.5, 125.3, 130.3, 130.3,
130.8, 133.2, 144.4, 163.9, 164.4 ppm. HPLC–MS (ESI): tR = 16.80 min,
m/z = 229 [M + H]+.
1-Methyl-10b-(p-tolyl)-1,10b-dihydropyrimido[2,1-a]isoindole-
2,6-dione (22): Colourless crystals (95 %). M.p. 183–184 °C. 1H NMR
(500 MHz, CDCl3): δ = 2.31 (s, 3 H, ArCH3), 3.31 (s, 3 H, 1-CH3), 5.64
(d, J = 7.44 Hz, 1-H, 4-H), 6.85 (d, J = 8.34 Hz, 2 H, ArH), 7.09 (d, J =
7.93 Hz, 1 H, ArH), 7.36 (d, J = 7.42 Hz, 2 H, ArH), 7.62–7.66 (m, 2 H,
ArH), 8.03–8.04 (m, 1 H, 3-H) ppm. 13C NMR (125.77 MHz, CDCl3):
δ = 21.0, 30.8, 81.1, 108.8, 125.0 126.0, 126.1, 129.5, 130.4, 130.6,
130.7, 133.5, 134.8, 139.2, 145.1, 165.1, 165.3 ppm. HPLC–MS (ESI):
tR = 25.70 min, m/z = 305 [M + H]+.
Preparation of Enantiomeric Pyrrolo[1,2-a]pyrimidine (+)-19
and Pyrimido[1,2-a]isoindole (–)-20: A solution of pyrrolo-
[1,2-a]quinazoline derivative (–)-4 (100 mg) or isoindolo[2,1-a]quin-
azoline derivative (+)-5 (100 mg) in MeCN (25 mL) was introduced
into the flow reactor at a temperature of 220 °C, using the same
flow rate (0.2 mL min–1), with a residence time of 15 min. The flow
output was collected, and the solvent was removed by evaporation.
The residue was dissolved in Et2O (1 mL). The resulting crystals were
collected by filtration and washed with Et2O. The 1H and 13C NMR
spectroscopic data for the optically active compounds were consist-
ent with those reported for the racemates.
(+)-(S)-1-Methyl-8a-(p-tolyl)-8,8a-dihydropyrrolo[1,2-a]pyr-
imidine-2,6(1H,7H)-dione [(+)-19]: Colourless crystals (97 %). M.p.
167–169 °C. [α]D25 = +195 (c = 0.3, MeOH); 97 % ee.
(–)-(S)-1-Methyl-1,10b-dihydropyrimido[2,1-a]isoindole-2,6-di-
one [(–)-20]: Colourless crystals (98 %). M.p. 203–205 °C [α]D25 =
–310 (c = 0.3, MeOH); 98 % ee.
Synthesis of Spiropyrimidinones 23–25: Spiroquinazoline deriva-
tives 8–16 (100 mg) were each introduced into the flow reactor in
solution in toluene/MeOH (4:1; 25 mL). The solution was inserted
into the reactor and passed through the heated reactor coil, at
150 °C for the epoxy-bridged 10, 13, and 16, or 240 °C for the
methylene-bridged 8, 9, 11, 12, 14, and 15, with a residence time
of 60 min. The flow output was collected, and the solvent was re-
moved by evaporation. The residue was dissolved in EtOAc/MeOH
(9:1); this material was transferred to a SiO2 column, which was
eluted with EtOAc/MeOH (9:1.
1,5-Diazaspiro[5.5]undec-3-en-2-one (23): Brownish crystals
(95 %). M.p. 160–164 °C. IR (KBr): ν˜ = 3263, 3025, 2939, 2863, 1627,
1516, 1434, 1337, 1213, 1122, 793, 730, 654 cm–1. 1H NMR (500 MHz,
Full Paper
[D6]DMSO): δ = 1.18–1.79 (m, 10 H, CH2), 4.31 (d, J = 7.2 Hz, 1 H, 3-
H), 6.74–6.77 (m, 2 H, 4-H, NH), 6.96 (s, 1 H, NH) ppm. 13C NMR
(125.77 MHz, CDCl3): δ = 21.7, 24.6, 36.9, 68.8, 92.2, 142.6, 166.2
ppm. HPLC–MS (ESI): tR = 10.72 min, m/z = 167 [M + H]+.
9-Benzyl-1,5,9-triazaspiro[5.5]undec-3-en-2-one (24): White
crystals (92 %). M.p. 192–195 °C. IR (KBr): ν˜ = 3243, 3026, 2947, 2808,
1614, 1527, 1424, 1219, 1104, 792, 739 cm–1. 1H NMR (500 MHz,
[D6]DMSO): δ = 1.96 (m, 4 H, CH2), 2.48 (m, 4 H, CH2), 3.53 (s, 2 H,
NCH2Ar), 4.49 (s, 1 H, NH), 4.80 (d, J = 7.39 Hz, 3-H, CH), 5.39 (s, 1
H, NH), 6.77–6.80 (t, J = 6.64 Hz, 1 H, 4-H), 7.28–7.34 (m, 5 H, ArH)
ppm. 13C NMR (125.77 MHz, [D6]DMSO): δ = 34.0, 36.6, 48.9, 49.4,
62.7, 67.3, 92.7, 127.3, 128.4, 129.1, 142.7, 166.0 ppm. HPLC–MS
(ESI): tR = 257.15 min, m/z = 258 [M + H]+.
1′H-Spiro[adamantane-2,2′-pyrimidin]-4′(3′H)-one (25): Brown-
ish crystals (86 %). M.p. 220–212 °C. IR (KBr): ν˜ = 3308, 2910, 1633,
1391, 1244, 1101, 783, 668, 618 cm–1. 1H NMR (500 MHz, CDCl3):
δ = 1.74–1.95 (m, 16 H, adamantane), 2.28 (m, 2 H, adamantane),
4.79 (m, 1 H, 5-H), 5.76 (m), 6.74–6.77 (m, 2 H, 4-H, NH), 6.85 (s, 1
H, 6-H) ppm. 13C NMR (125.77 MHz, CDCl3): δ = 26.1, 26.4, 32.3,
33.2. 35.0, 37.5, 71.9, 92.1, 142.8, 166.2 ppm. HPLC–MS (ESI): tR =
18.10 min, m/z = 219 [M + H]+.
General Procedure for Batch Reactions
Compounds 2–13 were prepared by the previously reported meth-
ods.[2l–2q]
Preparation of Spiroquinazolinone Derivatives 14–16: -aminor-
bornene carboxamide 1a, 1c, or 1d (1 mmol) was placed in a micro-
wave test tube (10 mL) containing a magnetic stirrer bar and EtOH
(2 mL). The reaction vial was then sealed with a Teflon cap, and
placed into the CEM Discover microwave reactor. The solution was
irradiated (150 W) for a period of 1 h at 100 °C. The resulting solu-
tion was transferred onto a SiO2 column, which was eluted with
toluene/MeOH (4:1).
(4aR*,5R*,8S*,8aS*)-4a,5,8,8a-Tetrahydro-1H-spiro[5,8-meth-
anoquinazoline-2,2′-adamantan]-4(3H)-one (14): Colourless
powder (75 %). M.p. 215–220 °C.
(4aS*,5R*,8S*,8aR*)-4a,5,8,8a-Tetrahydro-1H-spiro[5,8-meth-
anoquinazoline-2,2′-adamantan]-4(3H)-one (15): Colourless crys-
tals (77 %). M.p. 210–211 °C.
(4aS*,5R*,8S*,8aR*)-4a,5,8,8a-Tetrahydro-1H-spiro[5,8-epoxy-
quinazoline-2,2′-adamantan]-4(3H)-one (16): Colourless crystals
(76 %). M.p. 175–181 °C.
Microwave-Induced rDA Reactions of 8–16: Microwave-mediated
reactions were carried out in sealed reaction vials. Heterocycle 8–16
(200 mg) was placed in a microwave test tube (10 mL) containing
a magnetic stirrer bar and 1,2-DCB (2 mL). The reaction vial was
then sealed with a Teflon cap, and placed into the CEM Discover
microwave reactor. The solution was irradiated (250 W) for a period
of 30 min at 200 °C for 8, 9, 11, 12, 15, and 16, and at 180 °C
for 10, 13, and 16. The solution was cooled, and the solvent was
evaporated. The residue was dissolved in n-hexane/EtOAc (1:1) elu-
ent, and the resulting solution was transferred to a SiO2 column.
The yields of the products 23–25 are given in Figure 2. For 11, 14,
and 15, decomposition took place, and the formation of rDA prod-
ucts was not observed.
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ABSTRACT 
 
The helical folding ability of homooligomer β-pentapeptides constructed by using [1R,2R]-
2-aminocyclohexanecarboxylic acid ([1R,2R]-ACHC) monomers and comprising 
enantiomeric bicyclic β-amino acids {diexo-3-aminobicyclo[2.2.1]hept-5-ene-2-carboxylic 
acid (diexo-ABHEC) and diexo-3-amino-7-oxabicyclo[2.2.1]hept-5-ene-2-carboxylic acid 
(diexo-AOBHEC)} as well as Z-dehydro-β-alanine or β-alanine residues in the middle of the 
peptide chain has been studied. Both ab initio theory and spectroscopic techniques (NMR, 
ECD) proved unequivocally that oligomers incorporating [1R,2R,3S,4S]-ABHEC, 
[1R,2S,3R,4S]-AOBHEC and β-alanine as third residue tend to adopt a H14-helix motif. In 
contrast, if the middle unit is [1S,2S,3R,4R]-ABHEC or [1S,2R,3S,4R]-AOBHEC or Z-
dehydro-β-alanine, stable self-organization could not be observed. The results show that the 
different behavior of the incorporated enatiomeric pairs rely on steric hindrances caused by 
2 
 
the synperiplanar orientation of the ψ angle of the bicyclic residue. However, for Z-dehydro-
β-alanine, helix formation is excluded because of the conjugation of the carbon–carbon 
double bond and the residue flanking amide bonds, providing a planar orientation for these 
atoms yielding an elongated structure. 
KEYWORDS: bicyclic bridged amino acids, continuous-flow, chirality, foldamers helical 
structure, β-peptides, self-organization. 
 
INTRODUCTION 
Foldamers are artificial self-organizing biomimetic polymers. They have high tendency to 
fold into a conformationally ordered state in solution.
[1,2]
 The main motivation for designing 
peptidomimetic foldamers is the fact that these compounds are stable to proteolysis or 
metabolism and have better membrane permeability compared to α-peptide chains.[3,4] One of 
the most important representative of these peptidomimetic agents is β-peptides. The additional 
carbon atom in β-amino acids allows various alterations in substitution of the individual 
residues, which can result in remarkable changes of the complete folding behavior.
[5-24]
 β-
Peptides exhibit a wide range of bioactivities, e.g. antimicrobial,
[25,26]
 tertiary structural 
elements with ion-binding ability,
[9,27,28] 
and protein–protein interactions (PPIs) modifying 
activity.
[29-32]
 In addition, they have high importance in the creation of novel materials for 
tissue engineering.
[33]
 
Conformationally constrained β-peptide oligomers containing cyclic side-chains can fold 
into various helical conformations, such as H14,
[34,35]
 H12,
[36]
 H10/12
[36]
 and H14/16
[37]
 
helices. Homooligomers composed of [1R,2R]-2-aminocyclohexanecarboxylic acid ([1R,2R]-
ACHC) monomers form a highly stable H14 helix in various solvents.
[34,38]
 This H14 helix 
conformation contains three β-amino acid residues per turn, stabilized by H-bonds between 
C=O
i
 and NH
i-2 
pillars.
[39] 
Furthermore, there are information for the bulky, strongly 
hydrophobic bicyclic side-chains. For instance, peptides containing N-Boc-protected diexo-3-
aminobicyclo[2.2.1]hept-5-ene-2-carboxylic acid (diexo-ABHEC) enantiomer residues exhibit 
right- and left-handed consecutive 6-strands (6-membered intra-residue hydrogen bonding).
[40]
 
In contrast, with alternating backbone configuration of oligomers containing [2S,3R]/[2R,3S]-
ABHEC enantiomer units, with protected or free at both ends, they are not capable of helix 
formation; their secondary structures are a robust bend-strand
[41]
 or a circle-like fold.
[42]
 
Furthermore, β-peptides synthesized through the use of the bicyclic diexo-3-amino-7-
3 
 
oxabicyclo[2.2.1]hept-5-ene-2-carboxylic acid (diexo-AOBHEC) units adopt an 8-membered 
hydrogen-bonded ring conformation.
[43]
 
Herein, in order to study the effect of new structural elements on conformation, we 
examined the helix-forming property of oligomers containing enantiomeric bicyclic β-amino 
acid residues and their chemical derivatives. For this end, pentamers made of [1R,2R]-ACHC 
building blocks possessing an enantiomer of bicyclic residue in the middle of the peptide 
chain were assembled by revolutionary continuous-flow (CF) synthetic methods. As bridged 
residues, enantiomers of diexo-ABHEC and diexo-AOBHEC were used to compare the ability 
of folding regarding the configuration and study the effect of an oxygen-bridged residue on 
self-organization. From these structures, in a straightforward continuous-flow retro-Diels-
Alder (CF rDA) reaction step, an analogous derivative containing the Z-dehydro-β-alanine 
residue was prepared. To attain the β-alanine-containing foldamer, the saturation of the 
dehydro compound was carried out in a CF hydrogenation reactor. The combined use of NMR 
and ECD measurements with molecular modelling results showed the differences of helix 
stability in the abovementioned structures. 
RESULTS AND DISCUSSION 
We planned to create new pentameric systems built from [1R,2R]-ACHC comprising a 
bicyclic amino acid enantiomer in the third residue position. Therefore, β-peptides 1-4, 
illustrated in Scheme 1, were synthesized by a highly efficient continuous-flow solid-phase 
peptide synthesis (CF SPPS) technology developed in our laboratory.
[44]
 The technology 
allows the construction of various peptides by using very low, generally 1.5‐fold, amino‐acid 
excess. The peptides were elongated in the instrument, and the products were cleaved and 
purified through regular reversed‐phase HPLC methodology. The [1R,2R,3S,4S]-ABHEC and 
[1S,2S,3R,4R]-ABHEC enantiomers were incorporated into peptide 1 and 3, respectively. 
However, peptides 2 and 4 were synthesized by the utilization of racemic N-protected diexo-
AOBHEC amino acids and the resulting diastereomers were separated by means of RP-HPLC 
and their configuration was determined by NMR measurements and theoretical calculations. 
To investigate the effect of Z-dehydro-β-alanine on self-organization, compounds 1-4 
containing diexo-ABHEC and diexo-AOBHEC were subjected to CF rDA protocol reported 
recently
[45,46]
 (Scheme 1). As an illustration, solutions of β-peptide homooligomers 1-4 
dissolved in MeOH were introduced into the reactor by an HPLC pump. Heating the mixtures 
of 2 and 4 at 150 °C or 1 and 3 at 230 °C led to the expected oligomer 5 within a residence 
time of 14 min, with total conversion. Our last step was to study the folding behavior of 
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saturated β-alanine-containing peptide 6, by changing the third unit from Z-dehydro-β-alanine 
to β-alanine unit. Peptide 6 was prepared by saturating rDA product 5 in an H-Cube® CF 
hydrogenation reactor on a 10% Pd/charcoal catalyst at 50 °C and 50 bar affording oligomer 6 
in a good yield of 95%. The foldamers were analyzed by HPLC-MS and characterized 
through the use of different NMR methods, including TOCSY and ROESY, in different 
solvents: 4 mM solutions in H2O/D2O (90:10), CD3OH and DMSO-d6. The NMR signal 
dispersions were good for most of the compounds in these solvents; no signal broadening was 
observed and signal assignment could be performed in a straightforward manner. 
 
Scheme 1. Investigated foldamer structures composed of [1R,2R]-ACHC units incorporating 
[1R,2R,3S,4S]-ABHEC (1), [1R,2S,3R,4S]-AOBHEC* (2), [1S,2S,3R,4R]-ABHEC (3), 
[1S,2R,3S,4R]-AOBHEC* (4), Z-dehydro-β-alanine (5) and β-alanine (6) as third β-amino 
acid units. * The absolute configuration was determined by means of NMR investigations and 
theoretical calculations. 
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Furthermore, the analytical HPLC chromatograms of foldamers in diastereomeric relation, i.e. 
1 vs. 3 and 2 vs. 4, showed drastic differences. Foldamers 1 and 2 possess substantially higher 
retention times than 3 and 4. This finding suggests that 1 and 2 are more hydrophobic than 3 
and 4. According to previous results,
[37,47] 
the ordered helical structure is more hydrophobic 
since the amide bonds are in the center of the structure and only the hydrophobic side-chains 
interact with the chromatographic system. Consequently, helix formation might be anticipated 
for compounds 1 and 2.  
For a further assessment of the conformational stability, NH–ND amide proton exchange 
experiments were applied in CD3OD. Relative residual signal intensities are plotted in 
Figure 1. In all cases, N-terminal NH2 and C-terminal amide NH2 disappeared immediately 
after dissolution. For 3, an immediate proton exchange was observed indicating an unfolded 
structure. For 4 and 5, proton exchange occurred in about 1 hour demonstrating weak 
structure stabilizing H-bonds and poorly shielded amide protons. Significantly longer proton 
exchange times (10 hours, over 1 day) were shown for structures 1, 2 and 6. These 
observations may suggest highly shielded NH protons from the solvent and stable H-bonds, 
which indicate a helical secondary structure. These exchange rates are in accordance with the 
results measured for H14 helical β-peptides.[48] 
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Figure 1. NH–ND exchange plots for 1 (a), 2 (b), 6 (c) in CD3OD. ■: NH2; ○:NH3; ▲: NH4; 
◊: NH5; *: NH4+NH5. 
To characterize the high-resolution structure of the foldamers, ROESY NMR spectra were 
taken in H2O/D2O, CD3OH and DMSO-d6. For 1, 2, 6 long-range NOE interactions could be 
detected between Cβ protons of residues i=1,2 and Cα protons of residues (i+3) in all three 
solvents. Such correlations are typical for 14-helices (Figure 2). Additionally, in the spectrum 
of 2 NOE cross peak of NHi/CβHi+2 could be observed in CD3OH and DMSO, too, which is a 
further sign for H14 helix formation. Weak correlations were shown from CβHi–CαHi+3 in the 
case of 4 in CD3OH and DMSO, as well as for 3 in CD3OH. For 5 no long-range NOE cross 
peaks were seen regarding secondary structure interactions. These results suggest that a stable 
H14 helix formation was observed only for 1, 2 and 6. In contrast, for 3 and 4 only a 
considerably less stable helical organization was observed, while the introduction of the 
double bond to the back-bone ruled out the helix formation for 5.  
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Figure 2. Long-range NOE interactions representing evidences for secondary structure of 1 
(a), 2 (b) and 6 (c) in H2O/D2O (90:10), CD3OH and DMSO-d6. Spectra were taken at 298 K 
in 4 mM concentration. 
To further support the results, electronic circular dichroism spectra were recorded in water 
and methanol at room temperature. This method allowed us to compare the stability of H14 
helix in the investigated compounds and test the effect of built-in structural elements. The CD 
spectra of these β-peptides showed a broad maximum at 205–218 nm and a minimum at 183–
198 nm in both solvents―these values are characteristic for a H14-helical structure.[38] The 
decreased intensities for 3, 4 and 5 suggest the reduced stability of the secondary structure. In 
the case of 5 an additional absorption maximum at 262–266 nm could also be detected 
corresponding to the double bond inserted to the backbone. The practically identical 
absorption maxima and minima in water and methanol proved the absence of solvent-driven 
structural changes (Figure 3). 
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Figure 3. ECD spectra of 1 mM solutions of 1-6 in water (a,b) and methanol (c,d). 
To acquire a theoretical support to understand the experimental outcomes regarding the 
preferred stereoisomer concerning compounds 1 and 3 or compounds 2 and 4, high-level DFT 
calculations were performed. NMR and ECD measurements based on constrained molecular 
modelling structures were used as a preordered starting point for quantum level geometrical 
optimizations. For compounds 1-4 the geometries converged to the predicted H14 helix both 
in water and vacuum models. However, there are considerable differences in the stability of 
the helices. In Table 1 the total energies of the optimized structures in implicit solvent and 
vacuum are presented for each stereoisomer. The results show that quantumchemical 
investigations reinforce the experimental findings. Namely, compounds 1 and 2 have lower 
total energy in calculations than foldamers 3 and 4. This result is independent from the 
application of the implicit solvent model. A deeper investigation of the calculated 
conformations revealed structural discrepancies for these oligomers when compared with 
regular H14 helical β-peptides. It was found that the diexo-substituted bicyclic residue 
enforces overlapping of the HCβ3–(NH)3 protons for peptides 1 and 2 and (CO)3–HCα3 atoms 
for compounds 3 and 4. Such interaction is, in general, not favorable for helix formation. 
However, according to the observed results, the 1–2 hydrogen–hydrogen interaction is less 
problematic than the 1–2 oxygen–proton interaction. This phenomenon may rely on the larger 
size of the oxygen atom, since the electrostatic interaction of the partially negatively polarized 
oxygen atom and the hydrogen atom would be favorable. The effect of the size is underlined 
by interatomic distances. For HCβ3–(NH)3 it is 2.1 Å while for (CO)3–HCα3 it is 2.5 Å. The 
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enlarged distance indicates a more unfavorable interaction, which destabilizes the helical 
structure. This phenomenon can be examined by analyzing the φ angle for 1, 2 and ψ angle 
for 3 and 4. Both angles are enforced nearly to a synperiplanar conformation, because of the 
bridged bicyclic residue and hydrogen bond orientation of the H14 helix. This unfavorable 
interaction is partially compensated by the modification of the φ angle for 1, 2 and the ψ angle 
for 3 and 4. However, in the case of 1 and 2, where H–H interaction is the source of the 
problem, only a minor modification (22°) is satisfying for helix stabilization and 
synperiplanar interaction modification. However, in the case of 3 and 4, where H–O 
interaction causes the problem, the synperiplanar interaction might be minimized only by 
changing the ψ angle to 42° because of the larger size of the oxygen atom, which induces the 
destabilization of the H14 helix. 
 
Table 1 Total energies (in Hartree) of compound 1-4 optimized at M062x/cc-tzv level of 
theory in implicit solvent and vacuum.  
 1 
[1R,2R,3S,4S]- 
3 
[1S,2S,3R,4R]- 
2 
[1R,2S,3R,4S]- 
4 
[1S,2R,3S,4R]- 
 ABHEC AOBHEC 
implicit 
solvent 
-2110.73898 -2110.72979 -2146.65102 -2146.64546 
vacuum -2110.66906 -2110.65979  -2146.58150 -2146.57485 
 
According to the MM level conformational investigation, the same H14 helical conformation 
was found for 6, while a totally different 3D organization was found for 5. The Z-dehydro-β-
alanine moiety in the backbone completely changed the preferred geometry and an elongated 
structure was observed. The MM level optimized structures for compounds 1 and 5 are shown 
in Figure 4. 
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Figure 4. Optimized geometries for compounds 1 and 5 showing the H14 and the elongated 
geometries, respectively. 
As MM methods fix the bond lengths, QM optimizations were applied for compounds 5 and 6 
using the preordered MM optima to decipher the drastic structural differences. The results 
point to the conjugation in compound 5 between the double bond of the Z-dehydro-β-alanine 
residue and the flanking amides, since the bond length of (CO)2–(NH)3 and (CO)3–(NH)4 are 
longer, while the (NH)3–Cβ3 and Cα3–(CO)3 bonds are shorter than those for the unconjugated 
6 molecule. Moreover, the atoms of the Z-dehydro-β-alanine central residue and the atoms of 
the flanking amide bonds are within the same plane. The optimum bond lengths of QM level 
calculations for compound 5 and 6 are shown in Table 2.  
Table 2 Optimized bond lengths (in Å) of compound 5 and 6 at M062x/cc-tzv level implicit 
solvent calculations. The values in parenthesis are the results of the vacuum calculations. 
Compound 
Bond lengths 
(CO)2 – (NH)3 (CO)3 – (NH)4 (NH)3 – Cβ3 Cα3 – (CO)3 
5  1.38 (1.39) 1.35 (1.34) 1.37 (1.37) 1.47 (1.48) 
6  1.34 (1.35) 1.34 (1.34) 1.45 (1.45) 1.51 (1.51) 
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CONCLUSION 
In summary, CF methods allowed the efficient construction of six new pentameric β-
peptide systems, in which the ability of H14 helix formation was investigated. Our results on 
pentamers built from [1R,2R]-ACHC residues containing diexo-ABHEC or diexo-AOBHEC 
enantiomers as the third building block showed that the configuration of the middle element 
plays a crucial role on self-organization, and incorporation of an oxygen-bridged β-amino-
acid also enables folding. In the case of the incorporation of [1R,2R,3S,4S]-ABHEC (peptide 
1), [1R,2S,3R,4S]-AOBHEC (peptide 2) and β-alanine (peptide 6) as third residue, NOE 
interactions proved the H14 helical structure, additionally the typical absorption maxima and 
minima could be detected in ECD too. Long NH–ND exchange times (10 hours, over 1 day) 
showed a folded structure with strong H-bonding interactions and strongly shielded protons. 
ROESY-NMR, NH–ND exchange measurements, ECD investigations and ab initio 
calculations indicated no or weak folding features when [1S,2S,3R,4R]-ABHEC (peptide 3) or 
[1S,2R,3S,4R]-AOBHEC (peptide 4) was the third amino acid in chain. Z-Dehydro-β-alanine 
(peptide 5) as a rigid planar section of the system also resulted in an elongated self-
organization because of the conjugation of the double bond and the flanking amide bonds. In 
the case of 3 and 4, helix destabilization is caused by amide bond disorientation effect of the 
synperiplanar conformation overcoming the effect of H–O interaction of the ψ angle of the 
bicyclic residue. A similar interaction can be observed for 1 and 2 too, but because of the 
smaller size of the H atom the effect is less drastic, thus the H14 helix is not destabilized. 
These results serve as an important starting point for the design of helix assemblies involving 
the H14 helix. 
EXPERIMENTAL SECTION 
Peptide synthesis: Foldamers 1-4 were synthesized by means of continuous-flow solid-phase 
peptide synthesizer (CF-SPPS) involving 9H-fluoren-9-ylmethoxycarbonyl (Fmoc) 
technology. The peptide chains were elongated on Tentagel R RAM resin (0.20 mmol g
-1
) and 
the syntheses were carried out manually on a 0.1 mmol scale. Couplings were performed with 
HATU/DIPEA in dimethylformamide (2 mL, DMF) at 60 bar pressure, 70 °C temperature 
and 0.15 mL min
-1 
flow rate. For the deprotection step; a solution mixture (2mL) contains 2% 
DBU and 2% piperidine dissolved in DMF was used. The formed peptide sequences were 
cleaved from the resin with 95% trifluoroacetic acid (TFA), and 5% H2O at room temperature 
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for 3 h. TFA was then removed in vacuo, and the peptide was precipitated in dried 
diethylether. The resulting free peptide was filtered off, and dissolved in 10% aqueous acetic 
acid, and lyophilized. The crude peptides were purified by RP-HPLC.  
Synthesis of oligomer 5 via continuous-flow retro-Diels-Alder (CF-rDA) reaction: 
Solutions of β-peptides 1-4 (50 mg) dissolved in MeOH (50 mL) were loaded, respectively, 
into the flow reactor (Figure 1a). The system temperature was set to 150 °C (for 2 and 4) and 
230 °C (for 1 and 3), the pressure to 10 bar and the flow rate to 1 mL min
-1
. The solvent was 
evaporated, and the residue was dissolved in 10% aqueous acetic acid (10mL) and 
subsequently lyophilized. The oligomer 5 was afforded in good yields (from 1: 85 %; from 2: 
94 %; from 3: 79 %; from 4: 92 %). The peptide was analysed by HPLC-MS and purified by 
RP-HPLC techniques. 
Synthesis of oligomer 6: hydrogenation reaction was performed in an H-Cube
® 
(ThalesNano) 
flow reactor apparatus. Oligomer 5 (20 mg) was dissolved in MeOH (20 mL) and saturated on 
a 10% Pd/charcoal catalyst, the temperature was set to 50 °C, the pressure to 50 bar with a 
flow rate of 1 mL min
-1
. The flow output was collected and after evaporation of the solvent 
the resulting peptide was dissolved in 10% aqueous acetic acid, and lyophilized. The oligomer 
6 was obtained in a good yield (95%). The peptide 6 was analysed by HPLC-MS and the 
purity was determined by HPLC analysis.  
NMR experiments and signal assignments: NMR spectra were recorded at 298 K on Bruker 
Avance DRX 600 MHz and Avance III 500 MHz spectrometers. Samples in 4 mM 
concentration were dissolved in 0.5 ml CD3OH, DMSO-d6, and water (H2O/D2O 90:10) and 
transferred to 5 mm NMR sample tubes. Chemical shifts are given on the δ-scale and 
referenced to the solvent signal. Pulse programs of all experiments (
1
H, 2D-TOCSY, 2D-
ROESY) were taken from Bruker software library.  
CD measurements: CD spectra were measured on a Jasco J-1500 spectropolarimeter at room 
temperature in a 0.1 cm cylindrical quartz cell. Three spectra were accumulated for each 
sample. CD curves were corrected by the spectral contribution of the blank solvent.  The 
concentration of the sample solutions was 1 mM in CH3OH and H2O. Molar circular 
dichroism is given in M
-1
 cm
-1
. The data were normalized for the number of chromophores. 
Ab initio calculations: All calculations were performed with the Gaussian16 program 
package using the M06-2x functional in combination with cc-tvz basis set. For implicit water 
calculations the default PCM model was applied and the original convergence criteria were 
kept during geometrical optimization. Considering the protonation state of the pentamers the 
amino group at the N-terminal was always protonated during the calculations. 
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